<?xml version="1.0" encoding="UTF-8"?>
<GoldLabel drug="PENNSAID">
  <Text>
    <Section id="S1" name="adverse reactions">  6 ADVERSE REACTIONS

  The following adverse reactions are discussed in greater detail in other sections of the labeling:

 *  Cardiovascular Thrombotic Events [ see  Warnings and Precautions (5.1)   ] 
 *  GI Bleeding, Ulceration and Perforation [ see  Warnings and Precautions (5.2)   ] 
 *  Hepatotoxicity [ see  Warnings and Precautions (5.3)   ] 
 *  Hypertension [ see  Warnings and Precautions (5.4)   ] 
 *  Heart Failure and Edema [ see  Warnings and Precautions (5.5)   ] 
 *  Renal Toxicity and Hyperkalemia [ see  Warnings and Precautions (5.6)   ] 
 *  Anaphylactic Reactions [ see  Warnings and Precautions (5.7)   ] 
 *  Serious Skin Reactions [ see  Warnings and Precautions (5.9)   ] 
 *  Hematologic Toxicity [ see  Warnings and Precautions (5.11)   ] 
      EXCERPT:   The most common adverse reactions with PENNSAID are application site reactions. (  6.1  )
 

   To report SUSPECTED ADVERSE REACTIONS, contact Horizon Pharma USA Inc. at 1-866-479-6742 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.  

 

  6.1 Clinical Trials Experience

  Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

 The data described below reflect exposure to PENNSAID of 130 patients treated for 4 weeks (mean duration of 28 days) in one Phase 2 controlled trial. This population's mean age was approximately 60 years, 85% of patients were Caucasian, 65% were females, and all patients had primary osteoarthritis. The most common adverse events with PENNSAID were application site skin reactions. These events were the most common reason for withdrawing from the study.

     Application Site Reactions:  

 In this controlled trial, application site reactions were characterized by one or more of the following: dryness (22%), exfoliation (7%), erythema (4%), pruritus (2%), pain (2%), induration (2%), rash (2%), and scabbing (&lt;1%).

     Other Common Adverse Reactions:  

 Table 1 lists all adverse reactions occurring in &gt;1% of patients receiving PENNSAID, where the rate in the PENNSAID group exceeded vehicle, from a controlled study conducted in patients with osteoarthritis.

 Table 1: Incidence of Adverse Reactions Occurring in &gt;1% of Subjects with Osteoarthritis Using PENNSAID and More Often than in Subjects with OA Using Vehicle Control (Pooled) 
 Adverse Reaction                                       PENNSAIDN=130n (%)      Vehicle ControlN=129n (%)   
  
   Urinary tract infection                                    4 (3%)                     1 (&lt;1%)            
   Application site induration                                2 (2%)                     1 (&lt;1%)            
   Contusion                                                  2 (2%)                     1 (&lt;1%)            
   Sinus congestion                                           2 (2%)                     1 (&lt;1%)            
   Nausea                                                     2 (2%)                        0               
             PENNSAID 1.5%  
 

 The safety of PENNSAID 2% is based in part, on prior experience with PENNSAID 1.5%. The data described below reflect exposure to PENNSAID 1.5% of 911 patients treated between 4 and 12 weeks (mean duration of 49 days) in seven Phase 3 controlled trials, as well as exposure of 793 patients treated in an open-label study, including 463 patients treated for at least 6 months, and 144 patients treated for at least 12 months. The population mean age was approximately 60 years, 89% of patients were Caucasian, 64% were females, and all patients had primary osteoarthritis. The most common adverse events with PENNSAID 1.5% were application site skin reactions. These events were the most common reason for withdrawing from the studies.

     Application Site Reactions:  

 In controlled trials, application site reactions were characterized by one or more of the following: dryness, erythema, induration, vesicles, paresthesia, pruritus, vasodilation, acne, and urticaria. The most frequent of these reactions were dry skin (32%), contact dermatitis characterized by skin erythema and induration (9%), contact dermatitis with vesicles (2%) and pruritus (4%). In one controlled trial, a higher rate of contact dermatitis with vesicles (4%) was observed after treatment of 152 subjects with the combination of PENNSAID 1.5% and oral diclofenac. In the open-label uncontrolled long-term safety study, contact dermatitis occurred in 13% and contact dermatitis with vesicles in 10% of patients, generally within the first 6 months of exposure, leading to a withdrawal rate for an application site event of 14%.

     Other Common Adverse Reactions:  

 In controlled trials, subjects treated with PENNSAID 1.5% experienced some adverse events associated with the NSAID class more frequently than subjects using placebo (constipation, diarrhea, dyspepsia, nausea, flatulence, abdominal pain, edema; see  Table 2  ). The combination of PENNSAID 1.5% and oral diclofenac, compared to oral diclofenac alone, resulted in a higher rate of rectal hemorrhage (3% vs. less than 1%), and more frequent abnormal creatinine (12% vs. 7%), urea (20% vs. 12%), and hemoglobin (13% vs. 9%), but no difference in elevation of liver transaminases.

 Table 2 lists all adverse reactions occurring in &gt;=1% of patients receiving PENNSAID 1.5%, where the rate in the PENNSAID 1.5% group exceeded placebo, from seven controlled studies conducted in patients with osteoarthritis. Since these trials were of different durations, these percentages do not capture cumulative rates of occurrence.

 Table 2: Adverse Reactions Occurring in &gt;=1% of Patients Treated with PENNSAID 1.5% Topical Solution in Placebo and Oral Diclofenac-Controlled Trials 
 Treatment Group:                                       PENNSAID 1.5%N=911        Topical PlaceboN=332      
 Adverse Reaction                                              N (%)                      N (%)             
  
 Dry Skin (Application Site)                                 292 (32)                    17 (5)             
 Contact Dermatitis (Application Site)                        83 (9)                      6 (2)             
 Dyspepsia                                                    72 (8)                     13 (4)             
 Abdominal Pain                                               54 (6)                     10 (3)             
 Flatulence                                                   35 (4)                     1 (&lt;1)             
 Pruritus (Application Site)                                  34 (4)                      7 (2)             
 Diarrhea                                                     33 (4)                      7 (2)             
 Nausea                                                       33 (4)                      3 (1)             
 Pharyngitis                                                  40 (4)                     13 (4)             
 Constipation                                                 29 (3)                     1 (&lt;1)             
 Edema                                                        26 (3)                        0               
 Rash (Non-Application Site)                                  25 (3)                      5 (2)             
 Infection                                                    25 (3)                      8 (2)             
 Ecchymosis                                                   19 (2)                     1 (&lt;1)             
 Dry Skin (Non-Application Site)                              19 (2)                     1 (&lt;1)             
 Contact Dermatitis, vesicles (Application Site)              18 (2)                        0               
 Paresthesia (Non-Application Site)                           14 (2)                     3 (&lt;1)             
 Accidental Injury                                            22 (2)                      7 (2)             
 Pruritus (Non-Application Site)                              15 (2)                     2 (&lt;1)             
 Sinusitis                                                    10 (1)                     2 (&lt;1)             
 Halitosis                                                    11 (1)                     1 (&lt;1)             
 Application Site Reaction (not otherwise specified)           11 (1)                     3 (&lt;1)             
           6.2 Postmarketing Experience
   In postmarketing surveillance, the following adverse reactions have been reported during post- approval use of PENNSAID 1.5%. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

   Body as a Whole:  abdominal pain, accidental injury, allergic reactions, asthenia, back pain, body odor, chest pain, edema, face edema, halitosis, headache, neck rigidity, pain

   Cardiovascular:  palpitation, cardiovascular disorder

   Gastrointestinal:  diarrhea, dry mouth, dyspepsia, gastroenteritis, decreased appetite, lip swelling, mouth ulceration, nausea, rectal hemorrhage, ulcerative stomatitis, swollen tongue

   Metabolic and Nutritional:  creatinine increased

   Musculoskeletal:  leg cramps, myalgia

   Nervous:  depression, dizziness, drowsiness, lethargy, paresthesia at application site

   Respiratory:  asthma, dyspnea, laryngismus, laryngitis, pharyngitis, throat swelling

   Skin and Appendages: At the Application Site:  rash, skin burning sensation;

   Other Skin and Appendages Adverse Reactions:  eczema, skin discoloration, urticaria

   Special Senses:  abnormal vision, blurred vision, cataract, ear pain, eye disorder, eye pain, taste perversion

   Vascular:  blood pressure increased, hypertension

</Section>
    <Section id="S2" name="boxed warnings">

    BOXED WARNING: WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS

    WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS  

  EXCERPT:     WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS  

   See full prescribing information for complete boxed warning.  

 *  Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction, and stroke, which can be fatal This risk may occur early in treatment and may increase with duration of use (5.1) 
 *  PENNSAID is contraindicated in the setting of coronary artery bypass graft (CABG) surgery (4, 5.1) 
 *  NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events (5.2) 
    
 

    Cardiovascular Thrombotic Events  

 *  Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction, and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use. [see Warnings and Precautions (5.1)]. 
 *  PENNSAID is contraindicated in the setting of coronary artery bypass graft (CABG) surgery [see Contraindications (4) and Warnings and Precautions (5.1)]. 
        Gastrointestinal Bleeding, Ulceration, and Perforation  
 

 *  NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events [see Warnings and Precautions (5.2)]. 

</Section>
    <Section id="S3" name="warnings and precautions">   5 WARNINGS AND PRECAUTIONS

   EXCERPT:    *   Hepatotoxicity : Inform patients of warning signs and symptoms of hepatotoxicity. Discontinue if abnormal liver tests persist or worsen or if clinical signs and symptoms of liver disease develop (  5.3  ) 
 *   Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. Monitor blood pressure (  5.4  ,  7  ) 
 *   Heart Failure and Edema : Avoid use of PENNSAID in patients with severe heart failure unless benefits are expected to outweigh risk of worsening heart failure (  5.5  ) 
 *   Renal Toxicity : Monitor renal function in patients with renal or hepatic impairment, heart failure, dehydration, or hypovolemia. Avoid use of PENNSAID in patients with advanced renal disease unless benefits are expected to outweigh risk of worsening renal function (  5.6  ) 
 *   Anaphylactic Reactions : Seek emergency help if an anaphylactic reaction occurs (  5.7  ) 
 *   Exacerbation of Asthma Related to Aspirin Sensitivity : PENNSAID is contraindicated in patients with aspirin-sensitive asthma. Monitor patients with preexisting asthma (without aspirin sensitivity) (  5.8  ) 
 *   Serious Skin Reactions : Discontinue PENNSAID at first appearance of skin rash or other signs of hypersensitivity. (  5.9  ,  5.14  ) 
 *   Premature Closure of Fetal Ductus Arteriosus : Avoid use in pregnant women starting at 30 weeks gestation (  5.10  ,  8.1  ) 
 *   Hematologic Toxicity : Monitor hemoglobin or hematocrit in patients with any signs or symptoms of anemia (  5.11  ,  7  ). 
 *   Exposure to light: Avoid exposure of treated knee(s) to natural or artificial sunlight. (  5.11  ) 
 *   Eye Contact : Avoid contact of PENNSAID with eyes and mucosa. (  5.15  ) 
 *   Oral Nonsteroidal Anti-inflammatory Drugs : Avoid concurrent use with oral NSAIDs. (  5.16  ) 
    
 

   5.1 Cardiovascular Thrombotic Events

   Clinical trials of several COX-2 selective and nonselective NSAIDs of up to three years duration have shown an increased risk of serious cardiovascular (CV) thrombotic events, including myocardial infarction (MI), and stroke, which can be fatal. Based on available data, it is unclear that the risk for CV thrombotic events is similar for all NSAIDs. The relative increase in serious CV thrombotic events over baseline conferred by NSAID use appears to be similar in those with and without known CV disease or risk factors for CV disease. However, patients with known CV disease or risk factors had a higher absolute incidence of excess serious CV thrombotic events, due to their increased baseline rate. Some observational studies found that this increased risk of serious CV thrombotic events began as early as the first weeks of treatment. The increase in CV thrombotic risk has been observed most consistently at higher doses.  

 To minimize the potential risk for an adverse CV event in NSAID-treated patients, use the lowest effective dose for the shortest duration possible. Physicians and patients should remain alert for the development of such events, throughout the entire treatment course, even in the absence of previous CV symptoms. Patients should be informed about the symptoms of serious CV events and the steps to take if they occur.

 There is no consistent evidence that concurrent use of aspirin mitigates the increased risk of serious CV thrombotic events associated with NSAID use. The concurrent use of aspirin and an NSAID, such as diclofenac, increases the risk of serious gastrointestinal (GI) events [ see  Warnings and Precautions (5.2)    ].

    Status Post Coronary Artery Bypass Graft (CABG) Surgery  

 Two large, controlled, clinical trials of a COX-2 selective NSAID for the treatment of pain in the first 10-14 days following CABG surgery found an increased incidence of myocardial infarction and stroke. NSAIDs are contraindicated in the setting of CABG [ see  Contraindications (4)    ].

    Post-MI Patients  

 Observational studies conducted in the Danish National Registry have demonstrated that patients treated with NSAIDs in the post-MI period were at increased risk of reinfarction, CV-related death, and all-cause mortality beginning in the first week of treatment. In this same cohort, the incidence of death in the first year post-MI was 20 per 100 person years in NSAID-treated patients compared to 12 per 100 person years in non-NSAID exposed patients. Although the absolute rate of death declined somewhat after the first year post-MI, the increased relative risk of death in NSAID users persisted over at least the next four years of follow-up.

 Avoid the use of PENNSAID in patients with a recent MI unless the benefits are expected to outweigh the risk of recurrent CV thrombotic events. If PENNSAID is used in patients with a recent MI, monitor patients for signs of cardiac ischemia.

    5.2 Gastrointestinal Bleeding, Ulceration, and Perforation

  NSAIDs, including diclofenac, cause serious gastrointestinal (GI) adverse events including inflammation, bleeding, ulceration, and perforation of the esophagus, stomach, small intestine, or large intestine, which can be fatal. These serious adverse events can occur at any time, with or without warning symptoms, in patients treated with NSAIDs. Only one in five patients who develop a serious upper GI adverse event on NSAID therapy is symptomatic. Upper GI ulcers, gross bleeding, or perforation caused by NSAIDs occurred in approximately 1% of patients treated for 3-6 months, and in about 2%-4% of patients treated for one year. However, even short-term NSAID therapy is not without risk.

    Risk Factors for GI Bleeding, Ulceration, and Perforation  

 Patients with a prior history of peptic ulcer disease and/or GI bleeding who used NSAIDs had a greater than 10-fold increased risk for developing a GI bleed compared to patients without these risk factors. Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. Most postmarketing reports of fatal GI events occurred in elderly or debilitated patients. Additionally, patients with advanced liver disease and/or coagulopathy are at increased risk for GI bleeding.

    Strategies to Minimize the GI Risks in NSAID-treated patients:  

 *  Use the lowest effective dosage for the shortest possible duration. 
 *  Avoid administration of more than one NSAID at a time. 
 *  Avoid use in patients at higher risk unless benefits are expected to outweigh the increased risk of bleeding. For such patients, as well as those with active GI bleeding, consider alternate therapies other than NSAIDs. 
 *  Remain alert for signs and symptoms of GI ulceration and bleeding during NSAID therapy. 
 *  If a serious GI adverse event is suspected, promptly initiate evaluation and treatment, and discontinue PENNSAID until a serious GI adverse event is ruled out. 
 *  In the setting of concomitant use of low-dose aspirin for cardiac prophylaxis, monitor patients more closely for evidence of GI bleeding [ see  Drug Interactions (7)   ]. 
       5.3 Hepatotoxicity
 

  In clinical trials of oral diclofenac containing products, meaningful elevations (i.e., more than 3 times the ULN) of AST (SGOT) occurred in about 2% of approximately 5,700 patients at some time during diclofenac treatment (ALT was not measured in all studies).

 In a large, open-label, controlled trial of 3,700 patients treated with oral diclofenac for 2 - 6 months, patients were monitored first at 8 weeks and 1,200 patients were monitored again at 24 weeks. Meaningful elevations of ALT and/or AST occurred in about 4% of 3,700 patients and included marked elevations (greater than 8 times the ULN) in about 1% of the 3,700 patients. In that open-label study, a higher incidence of borderline (less than 3 times the ULN), moderate (3 to 8 times the ULN), and marked (greater than 8 times the ULN) elevations of ALT or AST was observed in patients receiving diclofenac when compared to other NSAIDs. Elevations in transaminases were seen more frequently in patients with osteoarthritis than in those with rheumatoid arthritis.

 Almost all meaningful elevations in transaminases were detected before patients became symptomatic. Abnormal tests occurred during the first 2 months of therapy with oral diclofenac in 42 of the 51 patients in all trials who developed marked transaminase elevations.

 In postmarketing reports, cases of drug-induced hepatotoxicity have been reported in the first month, and in some cases, the first 2 months of NSAID therapy, but can occur at any time during treatment with diclofenac.

 Postmarketing surveillance has reported cases of severe hepatic reactions, including liver necrosis, jaundice, fulminant hepatitis with and without jaundice, and liver failure. Some of these reported cases resulted in fatalities or liver transplantation.

 In a European retrospective population-based, case-controlled study, 10 cases of oral diclofenac associated drug-induced liver injury with current use compared with non-use of diclofenac were associated with a statistically significant 4-fold adjusted odds ratio of liver injury. In this particular study, based on an overall number of 10 cases of liver injury associated with diclofenac, the adjusted odds ratio increased further with female gender, doses of 150 mg or more, and duration of use for more than 90 days.

 Physicians should measure transaminases at baseline and periodically in patients receiving long-term therapy with diclofenac, because severe hepatotoxicity may develop without a prodrome of distinguishing symptoms. The optimum times for making the first and subsequent transaminase measurements are not known. Based on clinical trial data and postmarketing experiences, transaminases should be monitored within 4 to 8 weeks after initiating treatment with diclofenac. However, severe hepatic reactions can occur at any time during treatment with diclofenac.

 If abnormal liver tests persist or worsen, if clinical signs and/or symptoms consistent with liver disease develop, or if systemic manifestations occur (e.g., eosinophilia, rash, abdominal pain, diarrhea, dark urine, etc.), PENNSAID should be discontinued immediately.

 Inform patients of the warning signs and symptoms of hepatotoxicity (e.g., nausea, fatigue, lethargy, diarrhea, pruritus, jaundice, right upper quadrant tenderness, and "flu-like" symptoms). If clinical signs and symptoms consistent with liver disease develop, or if systemic manifestations occur (e.g., eosinophilia, rash, etc.), discontinue PENNSAID immediately, and perform a clinical evaluation of the patient.

 To minimize the potential risk for an adverse liver-related event in patients treated with PENNSAID, use the lowest effective dose for the shortest duration possible. Exercise caution when prescribing PENNSAID with concomitant drugs that are known to be potentially hepatotoxic (e.g., acetaminophen, antibiotics, antiepileptics).

    5.4 Hypertension

  NSAIDs, including PENNSAID, can lead to new onset of hypertension or worsening of preexisting hypertension, either of which may contribute to the increased incidence of CV events. Patients taking angiotensin converting enzyme (ACE) inhibitors, thiazide diuretics, or loop diuretics may have impaired response to these therapies when taking NSAIDs [ see  Drug Interactions (7)    ].

 Monitor blood pressure (BP) during the initiation of NSAID treatment and throughout the course of therapy.

    5.5 Heart Failure and Edema

   The Coxib and traditional NSAID Trialists' Collaboration meta-analysis of randomized controlled trials demonstrated an approximately two-fold increase in hospitalizations for heart failure in COX-2 selective treated patients and nonselective NSAID-treated patients compared to placebo-treated patients. In a Danish National Registry study of patients with heart failure, NSAID use increased the risk of MI, hospitalization for heart failure, and death.  

 Additionally, fluid retention and edema have been observed in some patients treated with NSAIDs. Use of diclofenac may blunt the CV effects of several therapeutic agents used to treat these medical conditions (e.g., diuretics, ACE inhibitors, or angiotensin receptor blockers [ARBs]) [ see  Drug Interactions (7)    ].

 Avoid the use of PENNSAID in patients with severe heart failure unless the benefits are expected to outweigh the risk of worsening heart failure. If PENNSAID is used in patients with severe heart failure, monitor patients for signs of worsening heart failure.

    5.6 Renal Toxicity and Hyperkalemia

   Renal Toxicity  

 Long-term administration of NSAIDs has resulted in renal papillary necrosis and other renal injury.

 Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. In these patients, administration of an NSAID may cause a dose-dependent reduction in prostaglandin formation and, secondarily, in renal blood flow, which may precipitate overt renal decompensation. Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE-inhibitors or ARBs, and the elderly. Discontinuation of NSAID therapy is usually followed by recovery to the pretreatment state.

 No information is available from controlled clinical studies regarding the use of PENNSAID in patients with advanced renal disease. The renal effects of PENNSAID may hasten the progression of renal dysfunction in patients with preexisting renal disease.

 Correct volume status in dehydrated or hypovolemic patients prior to initiating PENNSAID. Monitor renal function in patients with renal or hepatic impairment, heart failure, dehydration, or hypovolemia during use of PENNSAID [ see  Drug Interactions (7)    ]. Avoid the use of PENNSAID in patients with advanced renal disease unless the benefits are expected to outweigh the risk of worsening renal function. If PENNSAID is used in patients with advanced renal disease, monitor patients for signs of worsening renal function.

    Hyperkalemia  

 Increases in serum potassium concentration, including hyperkalemia, have been reported with use of NSAIDs, even in some patients without renal impairment. In patients with normal renal function, these effects have been attributed to a hyporeninemic-hypoaldosteronism state.

    5.7 Anaphylactic Reactions

  Diclofenac has been associated with anaphylactic reactions in patients with and without known hypersensitivity to diclofenac and in patients with aspirin-sensitive asthma [ see  Contraindications (4)  and  Warnings and Precautions (5.8)    ].

 Seek emergency help if an anaphylactic reaction occurs.

    5.8 Exacerbation of Asthma Related to Aspirin Sensitivity

  A subpopulation of patients with asthma may have aspirin-sensitive asthma which may include chronic rhinosinusitis complicated by nasal polyps; severe, potentially fatal bronchospasm; and/or intolerance to aspirin and other NSAIDs. Because cross-reactivity between aspirin and other NSAIDs has been reported in such aspirin-sensitive patients, PENNSAID is contraindicated in patients with this form of aspirin sensitivity [ see  Contraindications (4)    ]. When PENNSAID is used in patients with preexisting asthma (without known aspirin sensitivity), monitor patients for changes in the signs and symptoms of asthma.

    5.9 Serious Skin Reactions

  NSAIDs, including diclofenac, can cause serious skin adverse reactions such as exfoliative dermatitis, Stevens-Johnson Syndrome (SJS), and toxic epidermal necrolysis (TEN), which can be fatal. These serious events may occur without warning. Inform patients about the signs and symptoms of serious skin reactions, and to discontinue the use of PENNSAID at the first appearance of skin rash or any other sign of hypersensitivity. PENNSAID is contraindicated in patients with previous serious skin reactions to NSAIDs [ see  Contraindications (4)    ].

 Do not apply PENNSAID to open skin wounds, infections, inflammations, or exfoliative dermatitis, as it may affect absorption and tolerability of the drug.

    5.10 Premature Closure of Fetal Ductus Arteriosus

  Diclofenac may cause premature closure of the fetal ductus arteriosus. Avoid use of NSAIDs, including PENNSAID, in pregnant women starting at 30 weeks of gestation (third trimester) [ see  Use in Specific Populations (8.1)    ].

    5.11 Hematologic Toxicity

  Anemia has occurred in NSAID-treated patients. This may be due to occult or gross blood loss, fluid retention, or an incompletely described effect on erythropoiesis. If a patient treated with PENNSAID has any signs or symptoms of anemia, monitor hemoglobin or hematocrit.

 NSAIDs, including PENNSAID, may increase the risk of bleeding events. Co-morbid conditions such as coagulation disorders or concomitant use of warfarin, other anticoagulants, antiplatelet agents (e.g., aspirin), serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase this risk. Monitor these patients for signs of bleeding [ see  Drug Interactions (7)    ].

    5.12 Masking of Inflammation and Fever

  The pharmacological activity of PENNSAID in reducing inflammation, and possibly fever, may diminish the utility of diagnostic signs in detecting infections.

    5.13 Laboratory Monitoring

  Because serious GI bleeding, hepatotoxicity, and renal injury can occur without warning symptoms or signs, consider monitoring patients on long-term NSAID treatment with a CBC and a chemistry profile periodically [ see  Warnings and Precautions (5.2  ,  5.3  ,  5.6)    ].

    5.14 Sun Exposure

  Instruct patients to avoid exposure to natural or artificial sunlight on treated knee(s) because studies in animals indicated topical diclofenac treatment resulted in an earlier onset of ultraviolet light-induced skin tumors. The potential effects of PENNSAID on skin response to ultraviolet damage in humans are not known.

    5.15 Eye Exposure

  Avoid contact of PENNSAID with eyes and mucosa. Advise patients that if eye contact occurs, immediately wash out the eye with water or saline and consult a physician if irritation persists for more than an hour.

    5.16 Oral Nonsteroidal Anti-Inflammatory Drugs

  Concomitant use of oral NSAIDs with PENNSAID 1.5% resulted in a higher rate of rectal hemorrhage, more frequent abnormal creatinine, urea and hemoglobin. Therefore, do not use combination therapy with PENNSAID and an oral NSAID unless the benefit outweighs the risk and conduct periodic laboratory evaluations.

</Section>
  </Text>
  <IgnoredRegions>
    <IgnoredRegion len="19" name="heading" section="S1" start="2" />
    <IgnoredRegion len="26" name="heading" section="S3" start="3" />
    <IgnoredRegion len="1854" name="excerpt" section="S3" start="33" />
    <IgnoredRegion len="71" name="heading" section="S2" start="92" />
    <IgnoredRegion len="927" name="excerpt" section="S2" start="166" />
    <IgnoredRegion len="251" name="excerpt" section="S1" start="778" />
    <IgnoredRegion len="30" name="heading" section="S1" start="1033" />
    <IgnoredRegion len="36" name="heading" section="S3" start="1894" />
    <IgnoredRegion len="58" name="heading" section="S3" start="4885" />
    <IgnoredRegion len="18" name="heading" section="S3" start="7295" />
    <IgnoredRegion len="28" name="heading" section="S1" start="8518" />
    <IgnoredRegion len="16" name="heading" section="S3" start="11203" />
    <IgnoredRegion len="27" name="heading" section="S3" start="11719" />
    <IgnoredRegion len="35" name="heading" section="S3" start="12794" />
    <IgnoredRegion len="26" name="heading" section="S3" start="14681" />
    <IgnoredRegion len="57" name="heading" section="S3" start="15017" />
    <IgnoredRegion len="26" name="heading" section="S3" start="15701" />
    <IgnoredRegion len="49" name="heading" section="S3" start="16443" />
    <IgnoredRegion len="25" name="heading" section="S3" start="16730" />
    <IgnoredRegion len="38" name="heading" section="S3" start="17449" />
    <IgnoredRegion len="26" name="heading" section="S3" start="17653" />
    <IgnoredRegion len="17" name="heading" section="S3" start="17961" />
    <IgnoredRegion len="17" name="heading" section="S3" start="18311" />
    <IgnoredRegion len="46" name="heading" section="S3" start="18549" />
  </IgnoredRegions>
  <Mentions>
    <Mention id="M149" len="32" reason="from_drug_use" section="S1" start="129" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Instability cardiovascular" meddra_llt_id="10022453" meddra_pt="Cardiovascular disorder" meddra_pt_id="10007649" />
      <Normalization meddra_pt="Cardiovascular symptom" meddra_pt_id="10075534" />
    </Mention>
    <Mention id="M103" len="11" reason="from_drug_use" section="S1" start="209" type="OSE_Labeled_AE">
      <Normalization meddra_llt="GI bleed" meddra_llt_id="10018230" meddra_pt="Gastrointestinal haemorrhage" meddra_pt_id="10017955" />
    </Mention>
    <Mention id="M104" len="2,11" reason="from_drug_use" section="S1" start="209,237" type="OSE_Labeled_AE">
      <Normalization meddra_llt="GI perforation" meddra_llt_id="10018242" meddra_pt="Gastrointestinal perforation" meddra_pt_id="10018001" />
    </Mention>
    <Mention id="M105" len="2,10" reason="from_drug_use" section="S1" start="209,222" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Gastrointestinal ulcer" meddra_llt_id="10061459" meddra_pt="Gastrointestinal ulcer" meddra_pt_id="10061459" />
    </Mention>
    <Mention id="M106" len="14" reason="from_drug_use" section="S1" start="296" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hepatotoxicity" meddra_llt_id="10019851" meddra_pt="Hepatotoxicity" meddra_pt_id="10019851" />
      <Normalization meddra_pt="Liver disorder" meddra_pt_id="10024670" />
    </Mention>
    <Mention id="M107" len="12" reason="from_drug_use" section="S1" start="358" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hypertension" meddra_llt_id="10020772" meddra_pt="Hypertension" meddra_pt_id="10020772" />
    </Mention>
    <Mention id="M108" len="13" reason="from_drug_use" section="S1" start="418" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Heart failure" meddra_llt_id="10019279" meddra_pt="Cardiac failure" meddra_pt_id="10007554" />
    </Mention>
    <Mention id="M109" len="5" reason="from_drug_use" section="S1" start="436" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Edema" meddra_llt_id="10014210" meddra_pt="Oedema" meddra_pt_id="10030095" />
    </Mention>
    <Mention id="M110" len="14" reason="class_effect" section="S1" start="489" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Toxicity renal" meddra_llt_id="10044258" meddra_pt="Nephropathy toxic" meddra_pt_id="10029155" />
    </Mention>
    <Mention id="M111" len="12" reason="class_effect" section="S1" start="508" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hyperkalemia" meddra_llt_id="10020647" meddra_pt="Hyperkalaemia" meddra_pt_id="10020646" />
    </Mention>
    <Mention id="M112" len="22" reason="from_drug_use" section="S1" start="568" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Anaphylactic reaction" meddra_llt_id="10002198" meddra_pt="Anaphylactic reaction" meddra_pt_id="10002198" />
    </Mention>
    <Mention id="M113" len="14" reason="from_drug_use" section="S1" start="646" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Reaction skin" meddra_llt_id="10037971" meddra_pt="Skin reaction" meddra_pt_id="10040914" />
      <Normalization meddra_pt="Skin toxicity" meddra_pt_id="10059516" />
    </Mention>
    <Mention id="M114" len="20" reason="from_drug_use" section="S1" start="708" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Haematotoxicity" meddra_llt_id="10061188" meddra_pt="Haematotoxicity" meddra_pt_id="10061188" />
      <Normalization meddra_pt="Blood disorder" meddra_pt_id="10061590" />
    </Mention>
    <Mention id="M1" len="14" reason="indication" section="S1" start="1617" type="Not_AE_Candidate">
      <Normalization meddra_llt="Osteoarthritis" meddra_llt_id="10031161" meddra_pt="Osteoarthritis" meddra_pt_id="10031161" />
    </Mention>
    <Mention id="M115" len="31" reason="from_drug_use" section="S1" start="1683" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Application site reaction" meddra_llt_id="10003055" meddra_pt="Application site reaction" meddra_pt_id="10003055" />
    </Mention>
    <Mention id="M116" len="26" reason="from_drug_use" section="S1" start="1853" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Application site reaction" meddra_llt_id="10003055" meddra_pt="Application site reaction" meddra_pt_id="10003055" />
    </Mention>
    <Mention id="M117" len="16,7" reason="from_drug_use" section="S1" start="1853,1932" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Application site dryness" meddra_llt_id="10048943" meddra_pt="Application site dryness" meddra_pt_id="10048943" />
    </Mention>
    <Mention id="M118" len="16,11" reason="from_drug_use" section="S1" start="1853,1947" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Application site exfoliation" meddra_llt_id="10064578" meddra_pt="Application site exfoliation" meddra_pt_id="10064578" />
    </Mention>
    <Mention id="M119" len="16,8" reason="from_drug_use" section="S1" start="1853,1965" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Application site erythema" meddra_llt_id="10003041" meddra_pt="Application site erythema" meddra_pt_id="10003041" />
    </Mention>
    <Mention id="M120" len="16,8" reason="from_drug_use" section="S1" start="1853,1980" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Application site pruritus" meddra_llt_id="10003053" meddra_pt="Application site pruritus" meddra_pt_id="10003053" />
    </Mention>
    <Mention id="M121" len="16,4" reason="from_drug_use" section="S1" start="1853,1995" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Application site pain" meddra_llt_id="10003051" meddra_pt="Application site pain" meddra_pt_id="10003051" />
    </Mention>
    <Mention id="M122" len="16,10" reason="from_drug_use" section="S1" start="1853,2006" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Application site induration" meddra_llt_id="10063839" meddra_pt="Application site induration" meddra_pt_id="10063839" />
    </Mention>
    <Mention id="M123" len="16,4" reason="from_drug_use" section="S1" start="1853,2023" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Application site rash" meddra_llt_id="10003054" meddra_pt="Application site rash" meddra_pt_id="10003054" />
    </Mention>
    <Mention id="M124" len="16,8" reason="from_drug_use" section="S1" start="1853,2038" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Application site scabbing" meddra_llt_id="10052163" meddra_pt="Application site scab" meddra_pt_id="10066209" />
    </Mention>
    <Mention id="M2" len="14" reason="indication" section="S1" start="2287" type="Not_AE_Candidate">
      <Normalization meddra_llt="Osteoarthritis" meddra_llt_id="10031161" meddra_pt="Osteoarthritis" meddra_pt_id="10031161" />
    </Mention>
    <Mention id="M25" len="23" reason="from_drug_use" section="S1" start="2596" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Infection urinary tract" meddra_llt_id="10021872" meddra_pt="Urinary tract infection" meddra_pt_id="10046571" />
    </Mention>
    <Mention id="M26" len="27" reason="from_drug_use" section="S1" start="2705" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Application site induration" meddra_llt_id="10063839" meddra_pt="Application site induration" meddra_pt_id="10063839" />
    </Mention>
    <Mention id="M27" len="9" reason="from_drug_use" section="S1" start="2814" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Contusion" meddra_llt_id="10050584" meddra_pt="Contusion" meddra_pt_id="10050584" />
    </Mention>
    <Mention id="M28" len="16" reason="from_drug_use" section="S1" start="2923" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Sinus congestion" meddra_llt_id="10040742" meddra_pt="Sinus congestion" meddra_pt_id="10040742" />
    </Mention>
    <Mention id="M29" len="6" reason="from_drug_use" section="S1" start="3032" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Nausea" meddra_llt_id="10028813" meddra_pt="Nausea" meddra_pt_id="10028813" />
    </Mention>
    <Mention id="M3" len="14" reason="indication" section="S1" start="3726" type="Not_AE_Candidate">
      <Normalization meddra_llt="Osteoarthritis" meddra_llt_id="10031161" meddra_pt="Osteoarthritis" meddra_pt_id="10031161" />
    </Mention>
    <Mention id="M125" len="31" reason="from_drug_use" section="S1" start="3797" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Application site reaction" meddra_llt_id="10003055" meddra_pt="Application site reaction" meddra_pt_id="10003055" />
    </Mention>
    <Mention id="M9" len="26" reason="general_term" section="S1" start="3965" type="NonOSE_AE">
      <Normalization meddra_llt="Application site reaction" meddra_llt_id="10003055" meddra_pt="Application site reaction" meddra_pt_id="10003055" />
    </Mention>
    <Mention id="M126" len="16,7" reason="from_drug_use" section="S1" start="3965,4044" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Application site dryness" meddra_llt_id="10048943" meddra_pt="Application site dryness" meddra_pt_id="10048943" />
    </Mention>
    <Mention id="M127" len="16,8" reason="from_drug_use" section="S1" start="3965,4053" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Application site erythema" meddra_llt_id="10003041" meddra_pt="Application site erythema" meddra_pt_id="10003041" />
    </Mention>
    <Mention id="M128" len="16,10" reason="from_drug_use" section="S1" start="3965,4063" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Application site induration" meddra_llt_id="10063839" meddra_pt="Application site induration" meddra_pt_id="10063839" />
    </Mention>
    <Mention id="M129" len="16,8" reason="from_drug_use" section="S1" start="3965,4075" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Application site vesicles" meddra_llt_id="10048941" meddra_pt="Application site vesicles" meddra_pt_id="10048941" />
    </Mention>
    <Mention id="M130" len="16,11" reason="from_drug_use" section="S1" start="3965,4085" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Application site paresthesia" meddra_llt_id="10048940" meddra_pt="Application site paraesthesia" meddra_pt_id="10050103" />
    </Mention>
    <Mention id="M131" len="16,8" reason="from_drug_use" section="S1" start="3965,4098" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Application site pruritus" meddra_llt_id="10003053" meddra_pt="Application site pruritus" meddra_pt_id="10003053" />
    </Mention>
    <Mention id="M132" len="16,12" reason="from_drug_use" section="S1" start="3965,4108" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Application site reaction" meddra_llt_id="10003055" meddra_pt="Application site reaction" meddra_pt_id="10003055" />
    </Mention>
    <Mention id="M133" len="16,4" reason="from_drug_use" section="S1" start="3965,4122" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Application site acne" meddra_llt_id="10073457" meddra_pt="Application site acne" meddra_pt_id="10073457" />
    </Mention>
    <Mention id="M134" len="16,9" reason="from_drug_use" section="S1" start="3965,4132" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Application site urticaria" meddra_llt_id="10050104" meddra_pt="Application site urticaria" meddra_pt_id="10050104" />
    </Mention>
    <Mention id="M30" len="8" reason="from_drug_use" section="S1" start="4185" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dry skin" meddra_llt_id="10013786" meddra_pt="Dry skin" meddra_pt_id="10013786" />
    </Mention>
    <Mention id="M31" len="18" reason="from_drug_use" section="S1" start="4201" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Contact dermatitis" meddra_llt_id="10010790" meddra_pt="Dermatitis contact" meddra_pt_id="10012442" />
    </Mention>
    <Mention id="M10" len="13" reason="manifestation_or_complication" section="S1" start="4237" type="NonOSE_AE">
      <Normalization meddra_llt="Skin erythema" meddra_llt_id="10040842" meddra_pt="Erythema" meddra_pt_id="10015150" />
    </Mention>
    <Mention id="M11" len="10" reason="manifestation_or_complication" section="S1" start="4255" type="NonOSE_AE">
      <Normalization meddra_llt="Induration" meddra_llt_id="10060708" meddra_pt="Induration" meddra_pt_id="10060708" />
    </Mention>
    <Mention id="M135" len="32" reason="from_drug_use" section="S1" start="4272" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Contact dermatitis" meddra_llt_id="10010790" meddra_pt="Dermatitis contact" meddra_pt_id="10012442" />
    </Mention>
    <Mention id="M136" len="23,8" reason="from_drug_use" section="S1" start="4272,4314" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Contact dermatitis" meddra_llt_id="10010790" meddra_pt="Dermatitis contact" meddra_pt_id="10012442" />
    </Mention>
    <Mention id="M137" len="32" reason="from_drug_use" section="S1" start="4371" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Contact dermatitis" meddra_llt_id="10010790" meddra_pt="Dermatitis contact" meddra_pt_id="10012442" />
    </Mention>
    <Mention id="M32" len="18" reason="from_drug_use" section="S1" start="4568" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Contact dermatitis" meddra_llt_id="10010790" meddra_pt="Dermatitis contact" meddra_pt_id="10012442" />
    </Mention>
    <Mention id="M33" len="32" reason="from_drug_use" section="S1" start="4607" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Contact dermatitis" meddra_llt_id="10010790" meddra_pt="Dermatitis contact" meddra_pt_id="10012442" />
    </Mention>
    <Mention id="M34" len="12" reason="from_drug_use" section="S1" start="4985" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Constipation" meddra_llt_id="10010774" meddra_pt="Constipation" meddra_pt_id="10010774" />
    </Mention>
    <Mention id="M35" len="8" reason="from_drug_use" section="S1" start="4999" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Diarrhea" meddra_llt_id="10012727" meddra_pt="Diarrhoea" meddra_pt_id="10012735" />
    </Mention>
    <Mention id="M36" len="9" reason="from_drug_use" section="S1" start="5009" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dyspepsia-aggravated" meddra_llt_id="10048482" meddra_pt="Dyspepsia" meddra_pt_id="10013946" />
    </Mention>
    <Mention id="M37" len="6" reason="from_drug_use" section="S1" start="5020" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Nausea" meddra_llt_id="10028813" meddra_pt="Nausea" meddra_pt_id="10028813" />
    </Mention>
    <Mention id="M38" len="10" reason="from_drug_use" section="S1" start="5028" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Flatulence" meddra_llt_id="10016766" meddra_pt="Flatulence" meddra_pt_id="10016766" />
    </Mention>
    <Mention id="M39" len="14" reason="from_drug_use" section="S1" start="5040" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pain abdominal" meddra_llt_id="10033374" meddra_pt="Abdominal pain" meddra_pt_id="10000081" />
    </Mention>
    <Mention id="M40" len="5" reason="from_drug_use" section="S1" start="5056" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Edema" meddra_llt_id="10014210" meddra_pt="Oedema" meddra_pt_id="10030095" />
    </Mention>
    <Mention id="M5" len="17" reason="AE_from_drug_interaction" section="S1" start="5198" type="NonOSE_AE">
      <Normalization meddra_llt="Hemorrhage rectal" meddra_llt_id="10019583" meddra_pt="Rectal haemorrhage" meddra_pt_id="10038063" />
    </Mention>
    <Mention id="M6" len="19" reason="AE_from_drug_interaction" section="S1" start="5257" type="NonOSE_AE">
      <Normalization meddra_llt="Plasma creatinine abnormal" meddra_llt_id="10035276" meddra_pt="Blood creatinine abnormal" meddra_pt_id="10005481" />
    </Mention>
    <Mention id="M7" len="8,4" reason="AE_from_drug_interaction" section="S1" start="5257,5291" type="NonOSE_AE">
      <Normalization meddra_llt="Plasma urea abnormal" meddra_llt_id="10035459" meddra_pt="Blood urea abnormal" meddra_pt_id="10005846" />
    </Mention>
    <Mention id="M8" len="8,10" reason="AE_from_drug_interaction" section="S1" start="5257,5315" type="NonOSE_AE">
      <Normalization meddra_llt="Hemoglobin abnormal" meddra_llt_id="10019482" meddra_pt="Haemoglobin abnormal" meddra_pt_id="10018879" />
    </Mention>
    <Mention id="M12" len="32" reason="AE_only_as_instruction" section="S1" start="5361" type="NonOSE_AE">
      <Normalization meddra_llt="Transaminases increased" meddra_llt_id="10054889" meddra_pt="Transaminases increased" meddra_pt_id="10054889" />
    </Mention>
    <Mention id="M4" len="14" reason="indication" section="S1" start="5605" type="Not_AE_Candidate">
      <Normalization meddra_llt="Osteoarthritis" meddra_llt_id="10031161" meddra_pt="Osteoarthritis" meddra_pt_id="10031161" />
    </Mention>
    <Mention id="M138" len="26" reason="from_drug_use" section="S1" start="6109" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Application site dryness" meddra_llt_id="10048943" meddra_pt="Application site dryness" meddra_pt_id="10048943" />
    </Mention>
    <Mention id="M139" len="36" reason="from_drug_use" section="S1" start="6218" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Application site dermatitis" meddra_llt_id="10003036" meddra_pt="Application site dermatitis" meddra_pt_id="10003036" />
    </Mention>
    <Mention id="M41" len="9" reason="from_drug_use" section="S1" start="6327" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dyspepsia-aggravated" meddra_llt_id="10048482" meddra_pt="Dyspepsia" meddra_pt_id="10013946" />
    </Mention>
    <Mention id="M42" len="14" reason="from_drug_use" section="S1" start="6436" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pain abdominal" meddra_llt_id="10033374" meddra_pt="Abdominal pain" meddra_pt_id="10000081" />
    </Mention>
    <Mention id="M43" len="10" reason="from_drug_use" section="S1" start="6545" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Flatulence" meddra_llt_id="10016766" meddra_pt="Flatulence" meddra_pt_id="10016766" />
    </Mention>
    <Mention id="M140" len="26" reason="from_drug_use" section="S1" start="6654" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Application site pruritus" meddra_llt_id="10003053" meddra_pt="Application site pruritus" meddra_pt_id="10003053" />
    </Mention>
    <Mention id="M44" len="8" reason="from_drug_use" section="S1" start="6763" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Diarrhea" meddra_llt_id="10012727" meddra_pt="Diarrhoea" meddra_pt_id="10012735" />
    </Mention>
    <Mention id="M45" len="6" reason="from_drug_use" section="S1" start="6872" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Nausea" meddra_llt_id="10028813" meddra_pt="Nausea" meddra_pt_id="10028813" />
    </Mention>
    <Mention id="M46" len="11" reason="from_drug_use" section="S1" start="6981" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pharyngitis" meddra_llt_id="10034835" meddra_pt="Pharyngitis" meddra_pt_id="10034835" />
    </Mention>
    <Mention id="M151" len="12" reason="from_drug_use" section="S1" start="7090" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Constipation" meddra_llt_id="10010774" meddra_pt="Constipation" meddra_pt_id="10010774" />
    </Mention>
    <Mention id="M47" len="5" reason="from_drug_use" section="S1" start="7199" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Edema" meddra_llt_id="10014210" meddra_pt="Oedema" meddra_pt_id="10030095" />
    </Mention>
    <Mention id="M48" len="4" reason="from_drug_use" section="S1" start="7308" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Rash" meddra_llt_id="10037844" meddra_pt="Rash" meddra_pt_id="10037844" />
    </Mention>
    <Mention id="M49" len="9" reason="from_drug_use" section="S1" start="7417" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Infection" meddra_llt_id="10021789" meddra_pt="Infection" meddra_pt_id="10021789" />
    </Mention>
    <Mention id="M50" len="10" reason="from_drug_use" section="S1" start="7526" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Ecchymosis" meddra_llt_id="10014080" meddra_pt="Ecchymosis" meddra_pt_id="10014080" />
    </Mention>
    <Mention id="M51" len="8" reason="from_drug_use" section="S1" start="7635" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dry skin" meddra_llt_id="10013786" meddra_pt="Dry skin" meddra_pt_id="10013786" />
    </Mention>
    <Mention id="M141" len="18,17" reason="from_drug_use" section="S1" start="7744,7773" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Application site dermatitis" meddra_llt_id="10003036" meddra_pt="Application site dermatitis" meddra_pt_id="10003036" />
    </Mention>
    <Mention id="M52" len="11" reason="from_drug_use" section="S1" start="7853" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Paresthesia" meddra_llt_id="10033987" meddra_pt="Paraesthesia" meddra_pt_id="10033775" />
    </Mention>
    <Mention id="M24" len="17" reason="AE_rate_lteq_placebo" section="S1" start="7962" type="NonOSE_AE">
      <Normalization meddra_llt="Non-accidental injury" meddra_llt_id="10029527" meddra_pt="Injury" meddra_pt_id="10022116" />
    </Mention>
    <Mention id="M53" len="8" reason="from_drug_use" section="S1" start="8071" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pruritus" meddra_llt_id="10037087" meddra_pt="Pruritus" meddra_pt_id="10037087" />
    </Mention>
    <Mention id="M54" len="9" reason="from_drug_use" section="S1" start="8180" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Sinusitis" meddra_llt_id="10040753" meddra_pt="Sinusitis" meddra_pt_id="10040753" />
    </Mention>
    <Mention id="M55" len="9" reason="from_drug_use" section="S1" start="8289" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Halitosis" meddra_llt_id="10019058" meddra_pt="Breath odour" meddra_pt_id="10006326" />
    </Mention>
    <Mention id="M142" len="25" reason="from_drug_use" section="S1" start="8398" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Application site reaction" meddra_llt_id="10003055" meddra_pt="Application site reaction" meddra_pt_id="10003055" />
    </Mention>
    <Mention id="M13" len="15" reason="general_term" section="S1" start="8882" type="NonOSE_AE">
      <Normalization meddra_llt="General symptom" meddra_llt_id="10060891" meddra_pt="General symptom" meddra_pt_id="10060891" />
    </Mention>
    <Mention id="M56" len="14" reason="from_drug_use" section="S1" start="8900" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pain abdominal" meddra_llt_id="10033374" meddra_pt="Abdominal pain" meddra_pt_id="10000081" />
    </Mention>
    <Mention id="M57" len="17" reason="from_drug_use" section="S1" start="8916" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Non-accidental injury" meddra_llt_id="10029527" meddra_pt="Injury" meddra_pt_id="10022116" />
    </Mention>
    <Mention id="M58" len="18" reason="from_drug_use" section="S1" start="8935" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Drug hypersensitivity" meddra_llt_id="10013700" meddra_pt="Drug hypersensitivity" meddra_pt_id="10013700" />
      <Normalization meddra_pt="Hypersensitivity" meddra_pt_id="10020751" />
    </Mention>
    <Mention id="M59" len="8" reason="from_drug_use" section="S1" start="8955" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Asthenia" meddra_llt_id="10003549" meddra_pt="Asthenia" meddra_pt_id="10003549" />
    </Mention>
    <Mention id="M60" len="9" reason="from_drug_use" section="S1" start="8965" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pain back" meddra_llt_id="10033380" meddra_pt="Back pain" meddra_pt_id="10003988" />
    </Mention>
    <Mention id="M61" len="9" reason="from_drug_use" section="S1" start="8976" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Odor body" meddra_llt_id="10030092" meddra_pt="Skin odour abnormal" meddra_pt_id="10040904" />
    </Mention>
    <Mention id="M62" len="10" reason="from_drug_use" section="S1" start="8987" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pain chest" meddra_llt_id="10033387" meddra_pt="Chest pain" meddra_pt_id="10008479" />
    </Mention>
    <Mention id="M63" len="5" reason="from_drug_use" section="S1" start="8999" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Edema" meddra_llt_id="10014210" meddra_pt="Oedema" meddra_pt_id="10030095" />
    </Mention>
    <Mention id="M64" len="10" reason="from_drug_use" section="S1" start="9006" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Face edema" meddra_llt_id="10016025" meddra_pt="Face oedema" meddra_pt_id="10016029" />
    </Mention>
    <Mention id="M65" len="9" reason="from_drug_use" section="S1" start="9018" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Halitosis" meddra_llt_id="10019058" meddra_pt="Breath odour" meddra_pt_id="10006326" />
    </Mention>
    <Mention id="M66" len="8" reason="from_drug_use" section="S1" start="9029" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Headache" meddra_llt_id="10019211" meddra_pt="Headache" meddra_pt_id="10019211" />
    </Mention>
    <Mention id="M67" len="13" reason="from_drug_use" section="S1" start="9039" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Neck rigidity" meddra_llt_id="10028839" meddra_pt="Nuchal rigidity" meddra_pt_id="10058483" />
    </Mention>
    <Mention id="M68" len="4" reason="from_drug_use" section="S1" start="9054" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pain" meddra_llt_id="10033371" meddra_pt="Pain" meddra_pt_id="10033371" />
    </Mention>
    <Mention id="M14" len="14" reason="general_term" section="S1" start="9063" type="NonOSE_AE">
      <Normalization meddra_llt="Instability cardiovascular" meddra_llt_id="10022453" meddra_pt="Cardiovascular disorder" meddra_pt_id="10007649" />
      <Normalization meddra_pt="Cardiovascular symptom" meddra_pt_id="10075534" />
    </Mention>
    <Mention id="M69" len="11" reason="from_drug_use" section="S1" start="9080" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Palpitation" meddra_llt_id="10033556" meddra_pt="Palpitations" meddra_pt_id="10033557" />
    </Mention>
    <Mention id="M150" len="23" reason="from_drug_use" section="S1" start="9093" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Cardiovascular disorder" meddra_llt_id="10007649" meddra_pt="Cardiovascular disorder" meddra_pt_id="10007649" />
      <Normalization meddra_pt="Cardiovascular symptom" meddra_pt_id="10075534" />
    </Mention>
    <Mention id="M15" len="16" reason="general_term" section="S1" start="9121" type="NonOSE_AE">
      <Normalization meddra_llt="Disorder gastrointestinal" meddra_llt_id="10013225" meddra_pt="Gastrointestinal disorder" meddra_pt_id="10017944" />
    </Mention>
    <Mention id="M70" len="8" reason="from_drug_use" section="S1" start="9140" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Diarrhea" meddra_llt_id="10012727" meddra_pt="Diarrhoea" meddra_pt_id="10012735" />
    </Mention>
    <Mention id="M71" len="9" reason="from_drug_use" section="S1" start="9150" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dry mouth" meddra_llt_id="10013781" meddra_pt="Dry mouth" meddra_pt_id="10013781" />
    </Mention>
    <Mention id="M72" len="9" reason="from_drug_use" section="S1" start="9161" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dyspepsia-aggravated" meddra_llt_id="10048482" meddra_pt="Dyspepsia" meddra_pt_id="10013946" />
    </Mention>
    <Mention id="M73" len="15" reason="from_drug_use" section="S1" start="9172" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Gastroenteritis" meddra_llt_id="10017888" meddra_pt="Gastroenteritis" meddra_pt_id="10017888" />
    </Mention>
    <Mention id="M74" len="18" reason="from_drug_use" section="S1" start="9189" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Decreased appetite" meddra_llt_id="10061428" meddra_pt="Decreased appetite" meddra_pt_id="10061428" />
    </Mention>
    <Mention id="M148" len="12" reason="from_drug_use" section="S1" start="9209" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Lip swelling" meddra_llt_id="10024570" meddra_pt="Lip swelling" meddra_pt_id="10024570" />
    </Mention>
    <Mention id="M75" len="16" reason="from_drug_use" section="S1" start="9223" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Mouth ulceration" meddra_llt_id="10028034" meddra_pt="Mouth ulceration" meddra_pt_id="10028034" />
    </Mention>
    <Mention id="M76" len="6" reason="from_drug_use" section="S1" start="9241" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Nausea" meddra_llt_id="10028813" meddra_pt="Nausea" meddra_pt_id="10028813" />
    </Mention>
    <Mention id="M77" len="17" reason="from_drug_use" section="S1" start="9249" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hemorrhage rectal" meddra_llt_id="10019583" meddra_pt="Rectal haemorrhage" meddra_pt_id="10038063" />
    </Mention>
    <Mention id="M78" len="21" reason="from_drug_use" section="S1" start="9268" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Stomatitis ulcerative" meddra_llt_id="10042138" meddra_pt="Mouth ulceration" meddra_pt_id="10028034" />
    </Mention>
    <Mention id="M79" len="14" reason="from_drug_use" section="S1" start="9291" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Swollen tongue" meddra_llt_id="10042727" meddra_pt="Swollen tongue" meddra_pt_id="10042727" />
    </Mention>
    <Mention id="M16" len="25" reason="general_term" section="S1" start="9310" type="NonOSE_AE">
      <Normalization meddra_llt="Metabolic disorder" meddra_llt_id="10058097" meddra_pt="Metabolic disorder" meddra_pt_id="10058097" />
    </Mention>
    <Mention id="M80" len="20" reason="from_drug_use" section="S1" start="9338" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Creatinine increased" meddra_llt_id="10011368" meddra_pt="Blood creatinine increased" meddra_pt_id="10005483" />
    </Mention>
    <Mention id="M17" len="15" reason="general_term" section="S1" start="9363" type="NonOSE_AE">
      <Normalization meddra_llt="Musculoskeletal disorder" meddra_llt_id="10048592" meddra_pt="Musculoskeletal disorder" meddra_pt_id="10048592" />
    </Mention>
    <Mention id="M81" len="10" reason="from_drug_use" section="S1" start="9381" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Cramps leg" meddra_llt_id="10011297" meddra_pt="Muscle spasms" meddra_pt_id="10028334" />
    </Mention>
    <Mention id="M82" len="7" reason="from_drug_use" section="S1" start="9393" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Myalgia" meddra_llt_id="10028411" meddra_pt="Myalgia" meddra_pt_id="10028411" />
    </Mention>
    <Mention id="M18" len="7" reason="general_term" section="S1" start="9405" type="NonOSE_AE">
      <Normalization meddra_llt="Nervous system disorder" meddra_llt_id="10029202" meddra_pt="Nervous system disorder" meddra_pt_id="10029202" />
      <Normalization meddra_pt="Neurotoxicity" meddra_pt_id="10029350" />
      <Normalization meddra_pt="Neurological symptom" meddra_pt_id="10060860" />
    </Mention>
    <Mention id="M83" len="10" reason="from_drug_use" section="S1" start="9415" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Anxiety/depression" meddra_llt_id="10002872" meddra_pt="Depression" meddra_pt_id="10012378" />
    </Mention>
    <Mention id="M84" len="9" reason="from_drug_use" section="S1" start="9427" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dizziness" meddra_llt_id="10013573" meddra_pt="Dizziness" meddra_pt_id="10013573" />
    </Mention>
    <Mention id="M85" len="10" reason="from_drug_use" section="S1" start="9438" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Drowsiness" meddra_llt_id="10013649" meddra_pt="Somnolence" meddra_pt_id="10041349" />
    </Mention>
    <Mention id="M86" len="8" reason="from_drug_use" section="S1" start="9450" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Lethargy" meddra_llt_id="10024264" meddra_pt="Lethargy" meddra_pt_id="10024264" />
    </Mention>
    <Mention id="M143" len="31" reason="from_drug_use" section="S1" start="9460" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Application site paresthesia" meddra_llt_id="10048940" meddra_pt="Application site paraesthesia" meddra_pt_id="10050103" />
    </Mention>
    <Mention id="M19" len="11" reason="general_term" section="S1" start="9496" type="NonOSE_AE">
      <Normalization meddra_llt="Respiratory disorder" meddra_llt_id="10038683" meddra_pt="Respiratory disorder" meddra_pt_id="10038683" />
    </Mention>
    <Mention id="M87" len="6" reason="from_drug_use" section="S1" start="9510" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Asthma" meddra_llt_id="10003553" meddra_pt="Asthma" meddra_pt_id="10003553" />
    </Mention>
    <Mention id="M88" len="7" reason="from_drug_use" section="S1" start="9518" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dyspnea" meddra_llt_id="10013963" meddra_pt="Dyspnoea" meddra_pt_id="10013968" />
    </Mention>
    <Mention id="M89" len="11" reason="from_drug_use" section="S1" start="9527" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Laryngismus" meddra_llt_id="10023873" meddra_pt="Laryngospasm" meddra_pt_id="10023891" />
    </Mention>
    <Mention id="M90" len="10" reason="from_drug_use" section="S1" start="9540" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Laryngitis" meddra_llt_id="10023874" meddra_pt="Laryngitis" meddra_pt_id="10023874" />
    </Mention>
    <Mention id="M91" len="11" reason="from_drug_use" section="S1" start="9552" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pharyngitis" meddra_llt_id="10034835" meddra_pt="Pharyngitis" meddra_pt_id="10034835" />
    </Mention>
    <Mention id="M92" len="15" reason="from_drug_use" section="S1" start="9565" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Throat swelling" meddra_llt_id="10043525" meddra_pt="Pharyngeal oedema" meddra_pt_id="10034829" />
    </Mention>
    <Mention id="M20" len="19" reason="general_term" section="S1" start="9585" type="NonOSE_AE">
      <Normalization meddra_llt="Skin disorder" meddra_llt_id="10040831" meddra_pt="Skin disorder" meddra_pt_id="10040831" />
    </Mention>
    <Mention id="M144" len="16,4" reason="from_drug_use" section="S1" start="9613,9632" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Application site rash" meddra_llt_id="10003054" meddra_pt="Application site rash" meddra_pt_id="10003054" />
    </Mention>
    <Mention id="M145" len="16,22" reason="from_drug_use" section="S1" start="9613,9638" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Application site burning" meddra_llt_id="10048942" meddra_pt="Application site pain" meddra_pt_id="10003051" />
    </Mention>
    <Mention id="M21" len="43" reason="general_term" section="S1" start="9666" type="NonOSE_AE">
      <Normalization meddra_llt="Reaction skin" meddra_llt_id="10037971" meddra_pt="Skin reaction" meddra_pt_id="10040914" />
      <Normalization meddra_pt="Skin toxicity" meddra_pt_id="10059516" />
    </Mention>
    <Mention id="M93" len="6" reason="from_drug_use" section="S1" start="9712" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Eczema" meddra_llt_id="10014184" meddra_pt="Eczema" meddra_pt_id="10014184" />
    </Mention>
    <Mention id="M94" len="18" reason="from_drug_use" section="S1" start="9720" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Discoloration skin" meddra_llt_id="10013076" meddra_pt="Skin discolouration" meddra_pt_id="10040829" />
    </Mention>
    <Mention id="M95" len="9" reason="from_drug_use" section="S1" start="9740" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Urticaria" meddra_llt_id="10046735" meddra_pt="Urticaria" meddra_pt_id="10046735" />
    </Mention>
    <Mention id="M22" len="14" reason="general_term" section="S1" start="9754" type="NonOSE_AE">
      <Normalization meddra_llt="Cranial nerve disorder" meddra_llt_id="10061093" meddra_pt="Cranial nerve disorder" meddra_pt_id="10061093" />
    </Mention>
    <Mention id="M146" len="15" reason="from_drug_use" section="S1" start="9771" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Vision abnormal" meddra_llt_id="10047508" meddra_pt="Visual impairment" meddra_pt_id="10047571" />
    </Mention>
    <Mention id="M96" len="14" reason="from_drug_use" section="S1" start="9788" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Vision blurred" meddra_llt_id="10047513" meddra_pt="Vision blurred" meddra_pt_id="10047513" />
    </Mention>
    <Mention id="M97" len="8" reason="from_drug_use" section="S1" start="9804" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Cataract" meddra_llt_id="10007739" meddra_pt="Cataract" meddra_pt_id="10007739" />
    </Mention>
    <Mention id="M98" len="8" reason="from_drug_use" section="S1" start="9814" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pain ear" meddra_llt_id="10033393" meddra_pt="Ear pain" meddra_pt_id="10014020" />
    </Mention>
    <Mention id="M147" len="12" reason="from_drug_use" section="S1" start="9824" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Disorder eye" meddra_llt_id="10013221" meddra_pt="Eye disorder" meddra_pt_id="10015916" />
      <Normalization meddra_pt="Ocular toxicity" meddra_pt_id="10061137" />
    </Mention>
    <Mention id="M99" len="8" reason="from_drug_use" section="S1" start="9838" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pain eye" meddra_llt_id="10033397" meddra_pt="Eye pain" meddra_pt_id="10015958" />
    </Mention>
    <Mention id="M100" len="16" reason="from_drug_use" section="S1" start="9848" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Taste perversion" meddra_llt_id="10043137" meddra_pt="Dysgeusia" meddra_pt_id="10013911" />
    </Mention>
    <Mention id="M23" len="8" reason="general_term" section="S1" start="9869" type="NonOSE_AE">
      <Normalization meddra_llt="Disorder vascular" meddra_llt_id="10013282" meddra_pt="Angiopathy" meddra_pt_id="10059245" />
    </Mention>
    <Mention id="M101" len="24" reason="from_drug_use" section="S1" start="9880" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pressure blood increased" meddra_llt_id="10036640" meddra_pt="Blood pressure increased" meddra_pt_id="10005750" />
    </Mention>
    <Mention id="M102" len="12" reason="from_drug_use" section="S1" start="9906" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hypertension" meddra_llt_id="10020772" meddra_pt="Hypertension" meddra_pt_id="10020772" />
    </Mention>
    <Mention id="M159" len="32" reason="class_effect" section="S2" start="1222" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Cardiovascular disorder" meddra_llt_id="10007649" meddra_pt="Cardiovascular disorder" meddra_pt_id="10007649" />
      <Normalization meddra_pt="Cardiovascular symptom" meddra_pt_id="10075534" />
    </Mention>
    <Mention id="M157" len="21" reason="class_effect" section="S2" start="1266" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Myocardial infarction" meddra_llt_id="10028596" meddra_pt="Myocardial infarction" meddra_pt_id="10028596" />
    </Mention>
    <Mention id="M158" len="6" reason="class_effect" section="S2" start="1293" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Stroke" meddra_llt_id="10042244" meddra_pt="Cerebrovascular accident" meddra_pt_id="10008190" />
    </Mention>
    <Mention id="M155" len="5" reason="general_term" section="S2" start="1314" type="NonOSE_AE">
      <Normalization meddra_llt="Death" meddra_llt_id="10011906" meddra_pt="Death" meddra_pt_id="10011906" />
    </Mention>
    <Mention id="M160" len="21,8" reason="class_effect" section="S2" start="1711,1758" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Bleeding gastrointestinal" meddra_llt_id="10005116" meddra_pt="Gastrointestinal haemorrhage" meddra_pt_id="10017955" />
    </Mention>
    <Mention id="M161" len="21,10" reason="class_effect" section="S2" start="1711,1768" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Gastrointestinal ulcer" meddra_llt_id="10061459" meddra_pt="Gastrointestinal ulcer" meddra_pt_id="10061459" />
    </Mention>
    <Mention id="M164" len="16,14" reason="class_effect" section="S2" start="1711,1733" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Disorder gastrointestinal" meddra_llt_id="10013225" meddra_pt="Gastrointestinal disorder" meddra_pt_id="10017944" />
    </Mention>
    <Mention id="M162" len="18,10" reason="class_effect" section="S2" start="1784,1814" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Perforation of intestine" meddra_llt_id="10034421" meddra_pt="Intestinal perforation" meddra_pt_id="10022694" />
    </Mention>
    <Mention id="M163" len="26" reason="class_effect" section="S2" start="1784" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Perforation stomach" meddra_llt_id="10034430" meddra_pt="Gastric perforation" meddra_pt_id="10017815" />
    </Mention>
    <Mention id="M156" len="5" reason="general_term" section="S2" start="1839" type="NonOSE_AE">
      <Normalization meddra_llt="Death" meddra_llt_id="10011906" meddra_pt="Death" meddra_pt_id="10011906" />
    </Mention>
    <Mention id="M152" len="20" reason="preexisting_condition_or_risk_factor" section="S2" start="1976" type="Not_AE_Candidate">
      <Normalization meddra_llt="Peptic ulcer disease" meddra_llt_id="10034343" meddra_pt="Peptic ulcer" meddra_pt_id="10034341" />
    </Mention>
    <Mention id="M153" len="11" reason="preexisting_condition_or_risk_factor" section="S2" start="2004" type="Not_AE_Candidate">
      <Normalization meddra_llt="GI bleed" meddra_llt_id="10018230" meddra_pt="Gastrointestinal haemorrhage" meddra_pt_id="10017955" />
    </Mention>
    <Mention id="M154" len="9" reason="AE_only_as_instruction" section="S2" start="2048" type="NonOSE_AE">
      <Normalization meddra_llt="Disorder gastrointestinal" meddra_llt_id="10013225" meddra_pt="Gastrointestinal disorder" meddra_pt_id="10017944" />
    </Mention>
    <Mention id="M357" len="37" reason="class_effect" section="S3" start="2072" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Instability cardiovascular" meddra_llt_id="10022453" meddra_pt="Cardiovascular disorder" meddra_pt_id="10007649" />
      <Normalization meddra_pt="Cardiovascular symptom" meddra_pt_id="10075534" />
    </Mention>
    <Mention id="M339" len="25" reason="class_effect" section="S3" start="2121" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Myocardial infarction" meddra_llt_id="10028596" meddra_pt="Myocardial infarction" meddra_pt_id="10028596" />
    </Mention>
    <Mention id="M305" len="6" reason="class_effect" section="S3" start="2153" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Stroke" meddra_llt_id="10042244" meddra_pt="Cerebrovascular accident" meddra_pt_id="10008190" />
    </Mention>
    <Mention id="M262" len="5" reason="general_term" section="S3" start="2174" type="NonOSE_AE">
      <Normalization meddra_llt="Death" meddra_llt_id="10011906" meddra_pt="Death" meddra_pt_id="10011906" />
    </Mention>
    <Mention id="M266" len="20" reason="AE_only_as_instruction" section="S3" start="2238" type="NonOSE_AE">
      <Normalization meddra_llt="Cardiovascular disorder" meddra_llt_id="10007649" meddra_pt="Cardiovascular disorder" meddra_pt_id="10007649" />
      <Normalization meddra_pt="Cardiovascular symptom" meddra_pt_id="10075534" />
    </Mention>
    <Mention id="M267" len="20" reason="AE_only_as_instruction" section="S3" start="2319" type="NonOSE_AE">
      <Normalization meddra_llt="Cardiovascular disorder" meddra_llt_id="10007649" meddra_pt="Cardiovascular disorder" meddra_pt_id="10007649" />
      <Normalization meddra_pt="Cardiovascular symptom" meddra_pt_id="10075534" />
    </Mention>
    <Mention id="M165" len="10" reason="preexisting_condition_or_risk_factor" section="S3" start="2431" type="Not_AE_Candidate">
      <Normalization meddra_llt="Cardiovascular disorder" meddra_llt_id="10007649" meddra_pt="Cardiovascular disorder" meddra_pt_id="10007649" />
      <Normalization meddra_pt="Cardiovascular symptom" meddra_pt_id="10075534" />
    </Mention>
    <Mention id="M166" len="10" reason="preexisting_condition_or_risk_factor" section="S3" start="2462" type="Not_AE_Candidate">
      <Normalization meddra_llt="Cardiovascular disorder" meddra_llt_id="10007649" meddra_pt="Cardiovascular disorder" meddra_pt_id="10007649" />
      <Normalization meddra_pt="Cardiovascular symptom" meddra_pt_id="10075534" />
    </Mention>
    <Mention id="M167" len="10" reason="preexisting_condition_or_risk_factor" section="S3" start="2503" type="Not_AE_Candidate">
      <Normalization meddra_llt="Cardiovascular disorder" meddra_llt_id="10007649" meddra_pt="Cardiovascular disorder" meddra_pt_id="10007649" />
      <Normalization meddra_pt="Cardiovascular symptom" meddra_pt_id="10075534" />
    </Mention>
    <Mention id="M268" len="20" reason="AE_only_as_instruction" section="S3" start="2580" type="NonOSE_AE">
      <Normalization meddra_llt="Cardiovascular disorder" meddra_llt_id="10007649" meddra_pt="Cardiovascular disorder" meddra_pt_id="10007649" />
      <Normalization meddra_pt="Cardiovascular symptom" meddra_pt_id="10075534" />
    </Mention>
    <Mention id="M358" len="20" reason="class_effect" section="S3" start="2709" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Cardiovascular disorder" meddra_llt_id="10007649" meddra_pt="Cardiovascular disorder" meddra_pt_id="10007649" />
      <Normalization meddra_pt="Cardiovascular symptom" meddra_pt_id="10075534" />
    </Mention>
    <Mention id="M269" len="18" reason="AE_only_as_instruction" section="S3" start="2794" type="NonOSE_AE">
      <Normalization meddra_llt="Cardiovascular risk" meddra_llt_id="10078955" meddra_pt="Disease risk factor" meddra_pt_id="10078950" />
    </Mention>
    <Mention id="M263" len="8" reason="AE_only_as_instruction" section="S3" start="2916" type="NonOSE_AE">
      <Normalization meddra_llt="Cardiovascular disorder" meddra_llt_id="10007649" meddra_pt="Cardiovascular disorder" meddra_pt_id="10007649" />
      <Normalization meddra_pt="Cardiovascular symptom" meddra_pt_id="10075534" />
    </Mention>
    <Mention id="M264" len="11" reason="negation" section="S3" start="3170" type="NonOSE_AE">
      <Normalization meddra_llt="Cardiovascular symptom" meddra_llt_id="10075534" meddra_pt="Cardiovascular symptom" meddra_pt_id="10075534" />
      <Normalization meddra_pt="Cardiovascular disorder" meddra_pt_id="10007649" />
    </Mention>
    <Mention id="M265" len="9" reason="AE_only_as_instruction" section="S3" start="3241" type="NonOSE_AE">
      <Normalization meddra_llt="Cardiovascular disorder" meddra_llt_id="10007649" meddra_pt="Cardiovascular disorder" meddra_pt_id="10007649" />
      <Normalization meddra_pt="Cardiovascular symptom" meddra_pt_id="10075534" />
    </Mention>
    <Mention id="M216" len="20" reason="AE_only_as_instruction" section="S3" start="3393" type="NonOSE_AE">
      <Normalization meddra_llt="Cardiovascular disorder" meddra_llt_id="10007649" meddra_pt="Cardiovascular disorder" meddra_pt_id="10007649" />
      <Normalization meddra_pt="Cardiovascular symptom" meddra_pt_id="10075534" />
    </Mention>
    <Mention id="M217" len="28" reason="AE_from_drug_interaction" section="S3" start="3535" type="NonOSE_AE">
      <Normalization meddra_llt="Disorder gastrointestinal" meddra_llt_id="10013225" meddra_pt="Gastrointestinal disorder" meddra_pt_id="10017944" />
    </Mention>
    <Mention id="M194" len="4" reason="indication" section="S3" start="3760" type="Not_AE_Candidate">
      <Normalization meddra_llt="Pain" meddra_llt_id="10033371" meddra_pt="Pain" meddra_pt_id="10033371" />
    </Mention>
    <Mention id="M293" len="21" reason="AE_from_off_label" section="S3" start="3844" type="NonOSE_AE">
      <Normalization meddra_llt="Myocardial infarction" meddra_llt_id="10028596" meddra_pt="Myocardial infarction" meddra_pt_id="10028596" />
    </Mention>
    <Mention id="M294" len="6" reason="AE_from_off_label" section="S3" start="3870" type="NonOSE_AE">
      <Normalization meddra_llt="Stroke" meddra_llt_id="10042244" meddra_pt="Cerebrovascular accident" meddra_pt_id="10008190" />
    </Mention>
    <Mention id="M195" len="7" reason="preexisting_condition_or_risk_factor" section="S3" start="4112" type="Not_AE_Candidate">
      <Normalization meddra_llt="Post MI" meddra_llt_id="10036231" meddra_pt="Myocardial infarction" meddra_pt_id="10028596" />
    </Mention>
    <Mention id="M306" len="12" reason="class_effect" section="S3" start="4153" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Myocardial reinfarction" meddra_llt_id="10052318" meddra_pt="Myocardial infarction" meddra_pt_id="10028596" />
    </Mention>
    <Mention id="M340" len="16" reason="class_effect" section="S3" start="4167" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Cardiac death" meddra_llt_id="10049993" meddra_pt="Cardiac death" meddra_pt_id="10049993" />
    </Mention>
    <Mention id="M218" len="9" reason="general_term" section="S3" start="4199" type="NonOSE_AE">
      <Normalization meddra_llt="Death" meddra_llt_id="10011906" meddra_pt="Death" meddra_pt_id="10011906" />
    </Mention>
    <Mention id="M270" len="5" reason="general_term" section="S3" start="4289" type="NonOSE_AE">
      <Normalization meddra_llt="Death" meddra_llt_id="10011906" meddra_pt="Death" meddra_pt_id="10011906" />
    </Mention>
    <Mention id="M271" len="5" reason="general_term" section="S3" start="4472" type="NonOSE_AE">
      <Normalization meddra_llt="Death" meddra_llt_id="10011906" meddra_pt="Death" meddra_pt_id="10011906" />
    </Mention>
    <Mention id="M196" len="7" reason="preexisting_condition_or_risk_factor" section="S3" start="4517" type="Not_AE_Candidate">
      <Normalization meddra_llt="Post MI" meddra_llt_id="10036231" meddra_pt="Myocardial infarction" meddra_pt_id="10028596" />
    </Mention>
    <Mention id="M272" len="5" reason="general_term" section="S3" start="4557" type="NonOSE_AE">
      <Normalization meddra_llt="Death" meddra_llt_id="10011906" meddra_pt="Death" meddra_pt_id="10011906" />
    </Mention>
    <Mention id="M168" len="2" reason="preexisting_condition_or_risk_factor" section="S3" start="4690" type="Not_AE_Candidate">
      <Normalization meddra_llt="MI" meddra_llt_id="10027524" meddra_pt="Myocardial infarction" meddra_pt_id="10028596" />
    </Mention>
    <Mention id="M273" len="20" reason="AE_only_as_instruction" section="S3" start="4760" type="NonOSE_AE">
      <Normalization meddra_llt="Thrombotic vascular disease" meddra_llt_id="10077212" meddra_pt="Thrombosis" meddra_pt_id="10043607" />
    </Mention>
    <Mention id="M169" len="2" reason="preexisting_condition_or_risk_factor" section="S3" start="4828" type="Not_AE_Candidate">
      <Normalization meddra_llt="MI" meddra_llt_id="10027524" meddra_pt="Myocardial infarction" meddra_pt_id="10028596" />
    </Mention>
    <Mention id="M219" len="16" reason="AE_only_as_instruction" section="S3" start="4862" type="NonOSE_AE">
      <Normalization meddra_llt="Cardiac ischemia" meddra_llt_id="10055224" meddra_pt="Myocardial ischaemia" meddra_pt_id="10028600" />
    </Mention>
    <Mention id="M341" len="21,12" reason="from_drug_use" section="S3" start="4991,5038" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Gastrointestinal inflammation" meddra_llt_id="10064147" meddra_pt="Gastrointestinal inflammation" meddra_pt_id="10064147" />
    </Mention>
    <Mention id="M342" len="21,8" reason="from_drug_use" section="S3" start="4991,5052" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Bleeding gastrointestinal" meddra_llt_id="10005116" meddra_pt="Gastrointestinal haemorrhage" meddra_pt_id="10017955" />
    </Mention>
    <Mention id="M343" len="21,10" reason="from_drug_use" section="S3" start="4991,5062" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Gastrointestinal ulcer" meddra_llt_id="10061459" meddra_pt="Gastrointestinal ulcer" meddra_pt_id="10061459" />
    </Mention>
    <Mention id="M359" len="36" reason="from_drug_use" section="S3" start="4991" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Disorder gastrointestinal" meddra_llt_id="10013225" meddra_pt="Gastrointestinal disorder" meddra_pt_id="10017944" />
    </Mention>
    <Mention id="M344" len="18,15" reason="from_drug_use" section="S3" start="5078,5117" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Perforation small intestine" meddra_llt_id="10034429" meddra_pt="Small intestinal perforation" meddra_pt_id="10041103" />
    </Mention>
    <Mention id="M345" len="18,15" reason="from_drug_use" section="S3" start="5078,5137" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Perforation large intestine" meddra_llt_id="10034415" meddra_pt="Large intestine perforation" meddra_pt_id="10023804" />
    </Mention>
    <Mention id="M346" len="18,7" reason="from_drug_use" section="S3" start="5078,5108" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Perforation stomach" meddra_llt_id="10034430" meddra_pt="Gastric perforation" meddra_pt_id="10017815" />
    </Mention>
    <Mention id="M347" len="28" reason="from_drug_use" section="S3" start="5078" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Perforation of esophagus" meddra_llt_id="10034419" meddra_pt="Oesophageal perforation" meddra_pt_id="10030181" />
    </Mention>
    <Mention id="M274" len="5" reason="general_term" section="S3" start="5167" type="NonOSE_AE">
      <Normalization meddra_llt="Death" meddra_llt_id="10011906" meddra_pt="Death" meddra_pt_id="10011906" />
    </Mention>
    <Mention id="M220" len="22" reason="general_term" section="S3" start="5341" type="NonOSE_AE">
      <Normalization meddra_llt="Disorder gastrointestinal" meddra_llt_id="10013225" meddra_pt="Gastrointestinal disorder" meddra_pt_id="10017944" />
    </Mention>
    <Mention id="M307" len="15" reason="class_effect" section="S3" start="5397" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Gastrointestinal ulcer" meddra_llt_id="10061459" meddra_pt="Gastrointestinal ulcer" meddra_pt_id="10061459" />
    </Mention>
    <Mention id="M308" len="8,11" reason="class_effect" section="S3" start="5397,5433" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Upper gastrointestinal perforation" meddra_llt_id="10078413" meddra_pt="Upper gastrointestinal perforation" meddra_pt_id="10078413" />
    </Mention>
    <Mention id="M348" len="8,14" reason="class_effect" section="S3" start="5397,5414" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Upper gastrointestinal bleeding" meddra_llt_id="10071910" meddra_pt="Upper gastrointestinal haemorrhage" meddra_pt_id="10046274" />
    </Mention>
    <Mention id="M170" len="20" reason="preexisting_condition_or_risk_factor" section="S3" start="5740" type="Not_AE_Candidate">
      <Normalization meddra_llt="Peptic ulcer disease" meddra_llt_id="10034343" meddra_pt="Peptic ulcer" meddra_pt_id="10034341" />
    </Mention>
    <Mention id="M171" len="11" reason="preexisting_condition_or_risk_factor" section="S3" start="5768" type="Not_AE_Candidate">
      <Normalization meddra_llt="GI bleed" meddra_llt_id="10018230" meddra_pt="Gastrointestinal haemorrhage" meddra_pt_id="10017955" />
    </Mention>
    <Mention id="M309" len="8" reason="class_effect" section="S3" start="5855" type="OSE_Labeled_AE">
      <Normalization meddra_llt="GI bleed" meddra_llt_id="10018230" meddra_pt="Gastrointestinal haemorrhage" meddra_pt_id="10017955" />
    </Mention>
    <Mention id="M275" len="11" reason="AE_only_as_instruction" section="S3" start="5953" type="NonOSE_AE">
      <Normalization meddra_llt="GI bleed" meddra_llt_id="10018230" meddra_pt="Gastrointestinal haemorrhage" meddra_pt_id="10017955" />
    </Mention>
    <Mention id="M276" len="5" reason="general_term" section="S3" start="6255" type="NonOSE_AE">
      <Normalization meddra_llt="Death" meddra_llt_id="10011906" meddra_pt="Death" meddra_pt_id="10011906" />
    </Mention>
    <Mention id="M365" len="9" reason="from_drug_use" section="S3" start="6261" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Disorder gastrointestinal" meddra_llt_id="10013225" meddra_pt="Gastrointestinal disorder" meddra_pt_id="10017944" />
    </Mention>
    <Mention id="M172" len="13" reason="preexisting_condition_or_risk_factor" section="S3" start="6353" type="Not_AE_Candidate">
      <Normalization meddra_llt="Chronic liver disease" meddra_llt_id="10008953" meddra_pt="Liver disorder" meddra_pt_id="10024670" />
      <Normalization meddra_pt="Hepatotoxicity" meddra_pt_id="10019851" />
    </Mention>
    <Mention id="M173" len="12" reason="preexisting_condition_or_risk_factor" section="S3" start="6374" type="Not_AE_Candidate">
      <Normalization meddra_llt="Coagulopathy" meddra_llt_id="10009802" meddra_pt="Coagulopathy" meddra_pt_id="10009802" />
    </Mention>
    <Mention id="M296" len="11" reason="AE_only_as_instruction" section="S3" start="6413" type="NonOSE_AE">
      <Normalization meddra_llt="GI bleed" meddra_llt_id="10018230" meddra_pt="Gastrointestinal haemorrhage" meddra_pt_id="10017955" />
    </Mention>
    <Mention id="M221" len="8" reason="AE_only_as_instruction" section="S3" start="6734" type="NonOSE_AE">
      <Normalization meddra_llt="Bleeding" meddra_llt_id="10005103" meddra_pt="Haemorrhage" meddra_pt_id="10055798" />
    </Mention>
    <Mention id="M174" len="11" reason="preexisting_condition_or_risk_factor" section="S3" start="6792" type="Not_AE_Candidate">
      <Normalization meddra_llt="GI bleed" meddra_llt_id="10018230" meddra_pt="Gastrointestinal haemorrhage" meddra_pt_id="10017955" />
    </Mention>
    <Mention id="M222" len="13" reason="AE_only_as_instruction" section="S3" start="6897" type="NonOSE_AE">
      <Normalization meddra_llt="Gastrointestinal ulcer" meddra_llt_id="10061459" meddra_pt="Gastrointestinal ulcer" meddra_pt_id="10061459" />
    </Mention>
    <Mention id="M223" len="2,8" reason="AE_only_as_instruction" section="S3" start="6897,6915" type="NonOSE_AE">
      <Normalization meddra_llt="GI bleed" meddra_llt_id="10018230" meddra_pt="Gastrointestinal haemorrhage" meddra_pt_id="10017955" />
    </Mention>
    <Mention id="M224" len="16" reason="general_term" section="S3" start="6964" type="NonOSE_AE">
      <Normalization meddra_llt="Disorder gastrointestinal" meddra_llt_id="10013225" meddra_pt="Gastrointestinal disorder" meddra_pt_id="10017944" />
    </Mention>
    <Mention id="M225" len="16" reason="general_term" section="S3" start="7080" type="NonOSE_AE">
      <Normalization meddra_llt="Disorder gastrointestinal" meddra_llt_id="10013225" meddra_pt="Gastrointestinal disorder" meddra_pt_id="10017944" />
    </Mention>
    <Mention id="M226" len="11" reason="AE_only_as_instruction" section="S3" start="7241" type="NonOSE_AE">
      <Normalization meddra_llt="GI bleed" meddra_llt_id="10018230" meddra_pt="Gastrointestinal haemorrhage" meddra_pt_id="10017955" />
    </Mention>
    <Mention id="M349" len="10,12" reason="class_effect" section="S3" start="7389,7434" type="OSE_Labeled_AE">
      <Normalization meddra_llt="SGOT increased" meddra_llt_id="10040524" meddra_pt="Aspartate aminotransferase increased" meddra_pt_id="10003481" />
    </Mention>
    <Mention id="M350" len="13,3" reason="class_effect" section="S3" start="7794,7819" type="OSE_Labeled_AE">
      <Normalization meddra_llt="AST increased" meddra_llt_id="10003544" meddra_pt="Aspartate aminotransferase increased" meddra_pt_id="10003481" />
    </Mention>
    <Mention id="M351" len="17" reason="class_effect" section="S3" start="7794" type="OSE_Labeled_AE">
      <Normalization meddra_llt="ALT increased" meddra_llt_id="10001845" meddra_pt="Alanine aminotransferase increased" meddra_pt_id="10001551" />
    </Mention>
    <Mention id="M310" len="13,3" reason="from_drug_use" section="S3" start="8122,8143" type="OSE_Labeled_AE">
      <Normalization meddra_llt="AST increased" meddra_llt_id="10003544" meddra_pt="Aspartate aminotransferase increased" meddra_pt_id="10003481" />
    </Mention>
    <Mention id="M311" len="17" reason="from_drug_use" section="S3" start="8122" type="OSE_Labeled_AE">
      <Normalization meddra_llt="ALT increased" meddra_llt_id="10001845" meddra_pt="Alanine aminotransferase increased" meddra_pt_id="10001551" />
    </Mention>
    <Mention id="M364" len="27" reason="from_drug_use" section="S3" start="8224" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Transaminases increased" meddra_llt_id="10054889" meddra_pt="Transaminases increased" meddra_pt_id="10054889" />
    </Mention>
    <Mention id="M197" len="14" reason="indication" section="S3" start="8295" type="Not_AE_Candidate">
      <Normalization meddra_llt="Osteoarthritis" meddra_llt_id="10031161" meddra_pt="Osteoarthritis" meddra_pt_id="10031161" />
    </Mention>
    <Mention id="M198" len="20" reason="preexisting_condition_or_risk_factor" section="S3" start="8329" type="Not_AE_Candidate">
      <Normalization meddra_llt="Arthritis rheumatoid" meddra_llt_id="10003268" meddra_pt="Rheumatoid arthritis" meddra_pt_id="10039073" />
    </Mention>
    <Mention id="M297" len="27" reason="AE_only_as_instruction" section="S3" start="8375" type="NonOSE_AE">
      <Normalization meddra_llt="Transaminases increased" meddra_llt_id="10054889" meddra_pt="Transaminases increased" meddra_pt_id="10054889" />
    </Mention>
    <Mention id="M312" len="23" reason="from_drug_use" section="S3" start="8595" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Transaminase NOS increased" meddra_llt_id="10044346" meddra_pt="Transaminases increased" meddra_pt_id="10054889" />
    </Mention>
    <Mention id="M313" len="27" reason="from_drug_use" section="S3" start="8657" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Drug-induced hepatotoxicity" meddra_llt_id="10072937" meddra_pt="Drug-induced liver injury" meddra_pt_id="10072268" />
    </Mention>
    <Mention id="M360" len="17" reason="from_drug_use" section="S3" start="8898" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Disorder hepatic" meddra_llt_id="10013228" meddra_pt="Liver disorder" meddra_pt_id="10024670" />
      <Normalization meddra_pt="Hepatotoxicity" meddra_pt_id="10019851" />
    </Mention>
    <Mention id="M314" len="14" reason="from_drug_use" section="S3" start="8927" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Liver necrosis" meddra_llt_id="10024701" meddra_pt="Hepatic necrosis" meddra_pt_id="10019692" />
    </Mention>
    <Mention id="M315" len="8" reason="from_drug_use" section="S3" start="8943" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Jaundice" meddra_llt_id="10023126" meddra_pt="Jaundice" meddra_pt_id="10023126" />
    </Mention>
    <Mention id="M316" len="19" reason="from_drug_use" section="S3" start="8953" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hepatitis fulminant" meddra_llt_id="10019772" meddra_pt="Hepatitis fulminant" meddra_pt_id="10019772" />
    </Mention>
    <Mention id="M304" len="8" reason="manifestation_or_complication" section="S3" start="8990" type="NonOSE_AE">
      <Normalization meddra_llt="Jaundice" meddra_llt_id="10023126" meddra_pt="Jaundice" meddra_pt_id="10023126" />
    </Mention>
    <Mention id="M317" len="13" reason="from_drug_use" section="S3" start="9004" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Failure liver" meddra_llt_id="10016152" meddra_pt="Hepatic failure" meddra_pt_id="10019663" />
    </Mention>
    <Mention id="M277" len="10" reason="general_term" section="S3" start="9060" type="NonOSE_AE">
      <Normalization meddra_llt="Death" meddra_llt_id="10011906" meddra_pt="Death" meddra_pt_id="10011906" />
    </Mention>
    <Mention id="M318" len="25" reason="from_drug_use" section="S3" start="9207" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Drug-induced liver injury" meddra_llt_id="10072268" meddra_pt="Drug-induced liver injury" meddra_pt_id="10072268" />
    </Mention>
    <Mention id="M319" len="12" reason="from_drug_use" section="S3" start="9365" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Liver injury" meddra_llt_id="10067125" meddra_pt="Liver injury" meddra_pt_id="10067125" />
    </Mention>
    <Mention id="M320" len="12" reason="from_drug_use" section="S3" start="9447" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Liver injury" meddra_llt_id="10067125" meddra_pt="Liver injury" meddra_pt_id="10067125" />
    </Mention>
    <Mention id="M300" len="14" reason="AE_only_as_instruction" section="S3" start="9761" type="NonOSE_AE">
      <Normalization meddra_llt="Hepatotoxicity" meddra_llt_id="10019851" meddra_pt="Hepatotoxicity" meddra_pt_id="10019851" />
      <Normalization meddra_pt="Liver disorder" meddra_pt_id="10024670" />
    </Mention>
    <Mention id="M227" len="17" reason="general_term" section="S3" start="10104" type="NonOSE_AE">
      <Normalization meddra_llt="Disorder hepatic" meddra_llt_id="10013228" meddra_pt="Liver disorder" meddra_pt_id="10024670" />
      <Normalization meddra_pt="Hepatotoxicity" meddra_pt_id="10019851" />
    </Mention>
    <Mention id="M228" len="20" reason="AE_only_as_instruction" section="S3" start="10183" type="NonOSE_AE">
      <Normalization meddra_llt="Abnormal liver function tests" meddra_llt_id="10000158" meddra_pt="Liver function test abnormal" meddra_pt_id="10024690" />
    </Mention>
    <Mention id="M229" len="13" reason="AE_only_as_instruction" section="S3" start="10273" type="NonOSE_AE">
      <Normalization meddra_llt="Chronic liver disease" meddra_llt_id="10008953" meddra_pt="Liver disorder" meddra_pt_id="10024670" />
      <Normalization meddra_pt="Hepatotoxicity" meddra_pt_id="10019851" />
    </Mention>
    <Mention id="M230" len="12" reason="manifestation_or_complication" section="S3" start="10339" type="NonOSE_AE">
      <Normalization meddra_llt="Eosinophilia" meddra_llt_id="10014950" meddra_pt="Eosinophilia" meddra_pt_id="10014950" />
    </Mention>
    <Mention id="M231" len="4" reason="manifestation_or_complication" section="S3" start="10353" type="NonOSE_AE">
      <Normalization meddra_llt="Rash" meddra_llt_id="10037844" meddra_pt="Rash" meddra_pt_id="10037844" />
    </Mention>
    <Mention id="M232" len="14" reason="manifestation_or_complication" section="S3" start="10359" type="NonOSE_AE">
      <Normalization meddra_llt="Pain abdominal" meddra_llt_id="10033374" meddra_pt="Abdominal pain" meddra_pt_id="10000081" />
    </Mention>
    <Mention id="M233" len="8" reason="manifestation_or_complication" section="S3" start="10375" type="NonOSE_AE">
      <Normalization meddra_llt="Diarrhea" meddra_llt_id="10012727" meddra_pt="Diarrhoea" meddra_pt_id="10012735" />
    </Mention>
    <Mention id="M234" len="10" reason="manifestation_or_complication" section="S3" start="10385" type="NonOSE_AE">
      <Normalization meddra_llt="Brown urine" meddra_llt_id="10058129" meddra_pt="Chromaturia" meddra_pt_id="10008796" />
    </Mention>
    <Mention id="M235" len="14" reason="AE_only_as_instruction" section="S3" start="10504" type="NonOSE_AE">
      <Normalization meddra_llt="Hepatotoxicity" meddra_llt_id="10019851" meddra_pt="Hepatotoxicity" meddra_pt_id="10019851" />
      <Normalization meddra_pt="Liver disorder" meddra_pt_id="10024670" />
    </Mention>
    <Mention id="M236" len="6" reason="manifestation_or_complication" section="S3" start="10526" type="NonOSE_AE">
      <Normalization meddra_llt="Nausea" meddra_llt_id="10028813" meddra_pt="Nausea" meddra_pt_id="10028813" />
    </Mention>
    <Mention id="M237" len="7" reason="manifestation_or_complication" section="S3" start="10534" type="NonOSE_AE">
      <Normalization meddra_llt="Fatigue" meddra_llt_id="10016256" meddra_pt="Fatigue" meddra_pt_id="10016256" />
    </Mention>
    <Mention id="M238" len="8" reason="manifestation_or_complication" section="S3" start="10543" type="NonOSE_AE">
      <Normalization meddra_llt="Lethargy" meddra_llt_id="10024264" meddra_pt="Lethargy" meddra_pt_id="10024264" />
    </Mention>
    <Mention id="M239" len="8" reason="manifestation_or_complication" section="S3" start="10553" type="NonOSE_AE">
      <Normalization meddra_llt="Diarrhea" meddra_llt_id="10012727" meddra_pt="Diarrhoea" meddra_pt_id="10012735" />
    </Mention>
    <Mention id="M240" len="8" reason="manifestation_or_complication" section="S3" start="10563" type="NonOSE_AE">
      <Normalization meddra_llt="Pruritus" meddra_llt_id="10037087" meddra_pt="Pruritus" meddra_pt_id="10037087" />
    </Mention>
    <Mention id="M241" len="8" reason="manifestation_or_complication" section="S3" start="10573" type="NonOSE_AE">
      <Normalization meddra_llt="Jaundice" meddra_llt_id="10023126" meddra_pt="Jaundice" meddra_pt_id="10023126" />
    </Mention>
    <Mention id="M242" len="31" reason="manifestation_or_complication" section="S3" start="10583" type="NonOSE_AE">
      <Normalization meddra_llt="Upper abdominal tenderness" meddra_llt_id="10069064" meddra_pt="Abdominal tenderness" meddra_pt_id="10000097" />
    </Mention>
    <Mention id="M243" len="19" reason="manifestation_or_complication" section="S3" start="10620" type="NonOSE_AE">
      <Normalization meddra_llt="Flu-like symptoms" meddra_llt_id="10016797" meddra_pt="Influenza like illness" meddra_pt_id="10022004" />
    </Mention>
    <Mention id="M244" len="13" reason="AE_only_as_instruction" section="S3" start="10689" type="NonOSE_AE">
      <Normalization meddra_llt="Chronic liver disease" meddra_llt_id="10008953" meddra_pt="Liver disorder" meddra_pt_id="10024670" />
      <Normalization meddra_pt="Hepatotoxicity" meddra_pt_id="10019851" />
    </Mention>
    <Mention id="M245" len="12" reason="manifestation_or_complication" section="S3" start="10755" type="NonOSE_AE">
      <Normalization meddra_llt="Eosinophilia" meddra_llt_id="10014950" meddra_pt="Eosinophilia" meddra_pt_id="10014950" />
    </Mention>
    <Mention id="M246" len="4" reason="manifestation_or_complication" section="S3" start="10769" type="NonOSE_AE">
      <Normalization meddra_llt="Rash" meddra_llt_id="10037844" meddra_pt="Rash" meddra_pt_id="10037844" />
    </Mention>
    <Mention id="M278" len="19" reason="AE_only_as_instruction" section="S3" start="10914" type="NonOSE_AE">
      <Normalization meddra_llt="Disorder liver" meddra_llt_id="10013234" meddra_pt="Liver disorder" meddra_pt_id="10024670" />
      <Normalization meddra_pt="Hepatotoxicity" meddra_pt_id="10019851" />
    </Mention>
    <Mention id="M321" len="12" reason="from_drug_use" section="S3" start="11276" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hypertension" meddra_llt_id="10020772" meddra_pt="Hypertension" meddra_pt_id="10020772" />
    </Mention>
    <Mention id="M322" len="37" reason="from_drug_use" section="S3" start="11292" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hypertension" meddra_llt_id="10020772" meddra_pt="Hypertension" meddra_pt_id="10020772" />
    </Mention>
    <Mention id="M247" len="9" reason="manifestation_or_complication" section="S3" start="11392" type="NonOSE_AE">
      <Normalization meddra_llt="Cardiovascular disorder" meddra_llt_id="10007649" meddra_pt="Cardiovascular disorder" meddra_pt_id="10007649" />
      <Normalization meddra_pt="Cardiovascular symptom" meddra_pt_id="10075534" />
    </Mention>
    <Mention id="M323" len="13" reason="class_effect" section="S3" start="11926" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Heart failure" meddra_llt_id="10019279" meddra_pt="Cardiac failure" meddra_pt_id="10007554" />
    </Mention>
    <Mention id="M175" len="13" reason="preexisting_condition_or_risk_factor" section="S3" start="12107" type="Not_AE_Candidate">
      <Normalization meddra_llt="Heart failure" meddra_llt_id="10019279" meddra_pt="Cardiac failure" meddra_pt_id="10007554" />
    </Mention>
    <Mention id="M324" len="2" reason="class_effect" section="S3" start="12154" type="OSE_Labeled_AE">
      <Normalization meddra_llt="MI" meddra_llt_id="10027524" meddra_pt="Myocardial infarction" meddra_pt_id="10028596" />
    </Mention>
    <Mention id="M325" len="13" reason="class_effect" section="S3" start="12178" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Heart failure" meddra_llt_id="10019279" meddra_pt="Cardiac failure" meddra_pt_id="10007554" />
    </Mention>
    <Mention id="M279" len="5" reason="general_term" section="S3" start="12197" type="NonOSE_AE">
      <Normalization meddra_llt="Death" meddra_llt_id="10011906" meddra_pt="Death" meddra_pt_id="10011906" />
    </Mention>
    <Mention id="M326" len="15" reason="class_effect" section="S3" start="12222" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Fluid retention" meddra_llt_id="10016807" meddra_pt="Fluid retention" meddra_pt_id="10016807" />
    </Mention>
    <Mention id="M327" len="5" reason="class_effect" section="S3" start="12242" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Edema" meddra_llt_id="10014210" meddra_pt="Oedema" meddra_pt_id="10030095" />
    </Mention>
    <Mention id="M280" len="10" reason="AE_only_as_instruction" section="S3" start="12337" type="NonOSE_AE">
      <Normalization meddra_llt="Cardiovascular disorder" meddra_llt_id="10007649" meddra_pt="Cardiovascular disorder" meddra_pt_id="10007649" />
      <Normalization meddra_pt="Cardiovascular symptom" meddra_pt_id="10075534" />
    </Mention>
    <Mention id="M176" len="13" reason="preexisting_condition_or_risk_factor" section="S3" start="12579" type="Not_AE_Candidate">
      <Normalization meddra_llt="Heart failure" meddra_llt_id="10019279" meddra_pt="Cardiac failure" meddra_pt_id="10007554" />
    </Mention>
    <Mention id="M248" len="23" reason="AE_only_as_instruction" section="S3" start="12650" type="NonOSE_AE">
      <Normalization meddra_llt="Heart failure" meddra_llt_id="10019279" meddra_pt="Cardiac failure" meddra_pt_id="10007554" />
    </Mention>
    <Mention id="M177" len="13" reason="preexisting_condition_or_risk_factor" section="S3" start="12719" type="Not_AE_Candidate">
      <Normalization meddra_llt="Heart failure" meddra_llt_id="10019279" meddra_pt="Cardiac failure" meddra_pt_id="10007554" />
    </Mention>
    <Mention id="M249" len="23" reason="AE_only_as_instruction" section="S3" start="12764" type="NonOSE_AE">
      <Normalization meddra_llt="Heart failure" meddra_llt_id="10019279" meddra_pt="Cardiac failure" meddra_pt_id="10007554" />
    </Mention>
    <Mention id="M328" len="24" reason="class_effect" section="S3" start="12904" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Papillary necrosis renal" meddra_llt_id="10033699" meddra_pt="Renal papillary necrosis" meddra_pt_id="10038491" />
    </Mention>
    <Mention id="M352" len="12" reason="class_effect" section="S3" start="12939" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Renal injury" meddra_llt_id="10061481" meddra_pt="Renal injury" meddra_pt_id="10061481" />
    </Mention>
    <Mention id="M353" len="14" reason="class_effect" section="S3" start="12955" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Toxicity renal" meddra_llt_id="10044258" meddra_pt="Nephropathy toxic" meddra_pt_id="10029155" />
    </Mention>
    <Mention id="M295" len="12,16" reason="manifestation_or_complication" section="S3" start="13167,13225" type="NonOSE_AE">
      <Normalization meddra_llt="Renal hypoperfusion" meddra_llt_id="10073710" meddra_pt="Renal ischaemia" meddra_pt_id="10063897" />
    </Mention>
    <Mention id="M329" len="36" reason="class_effect" section="S3" start="13167" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Increased effect" meddra_llt_id="10021660" meddra_pt="Drug effect increased" meddra_pt_id="10013683" />
    </Mention>
    <Mention id="M281" len="20" reason="manifestation_or_complication" section="S3" start="13271" type="NonOSE_AE">
      <Normalization meddra_llt="Renal impairment" meddra_llt_id="10062237" meddra_pt="Renal impairment" meddra_pt_id="10062237" />
    </Mention>
    <Mention id="M178" len="23" reason="preexisting_condition_or_risk_factor" section="S3" start="13351" type="Not_AE_Candidate">
      <Normalization meddra_llt="Impaired renal function" meddra_llt_id="10021523" meddra_pt="Renal impairment" meddra_pt_id="10062237" />
    </Mention>
    <Mention id="M179" len="11" reason="preexisting_condition_or_risk_factor" section="S3" start="13376" type="Not_AE_Candidate">
      <Normalization meddra_llt="Dehydration" meddra_llt_id="10012174" meddra_pt="Dehydration" meddra_pt_id="10012174" />
    </Mention>
    <Mention id="M180" len="11" reason="preexisting_condition_or_risk_factor" section="S3" start="13389" type="Not_AE_Candidate">
      <Normalization meddra_llt="Hypovolemia" meddra_llt_id="10021139" meddra_pt="Hypovolaemia" meddra_pt_id="10021137" />
    </Mention>
    <Mention id="M181" len="13" reason="preexisting_condition_or_risk_factor" section="S3" start="13402" type="Not_AE_Candidate">
      <Normalization meddra_llt="Heart failure" meddra_llt_id="10019279" meddra_pt="Cardiac failure" meddra_pt_id="10007554" />
    </Mention>
    <Mention id="M182" len="17" reason="preexisting_condition_or_risk_factor" section="S3" start="13417" type="Not_AE_Candidate">
      <Normalization meddra_llt="Hepatic function abnormal" meddra_llt_id="10019670" meddra_pt="Hepatic function abnormal" meddra_pt_id="10019670" />
    </Mention>
    <Mention id="M183" len="13" reason="preexisting_condition_or_risk_factor" section="S3" start="13715" type="Not_AE_Candidate">
      <Normalization meddra_llt="Renal disease" meddra_llt_id="10051051" meddra_pt="Nephropathy" meddra_pt_id="10029151" />
    </Mention>
    <Mention id="M361" len="13" reason="from_drug_use" section="S3" start="13734" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Disorder renal" meddra_llt_id="10013263" meddra_pt="Renal disorder" meddra_pt_id="10038428" />
    </Mention>
    <Mention id="M354" len="32" reason="from_drug_use" section="S3" start="13775" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Kidney dysfunction" meddra_llt_id="10023417" meddra_pt="Renal impairment" meddra_pt_id="10062237" />
    </Mention>
    <Mention id="M184" len="13" reason="preexisting_condition_or_risk_factor" section="S3" start="13837" type="Not_AE_Candidate">
      <Normalization meddra_llt="Renal disease" meddra_llt_id="10051051" meddra_pt="Nephropathy" meddra_pt_id="10029151" />
    </Mention>
    <Mention id="M199" len="10" reason="preexisting_condition_or_risk_factor" section="S3" start="13879" type="Not_AE_Candidate">
      <Normalization meddra_llt="Dehydration" meddra_llt_id="10012174" meddra_pt="Dehydration" meddra_pt_id="10012174" />
    </Mention>
    <Mention id="M200" len="11" reason="preexisting_condition_or_risk_factor" section="S3" start="13893" type="Not_AE_Candidate">
      <Normalization meddra_llt="Hypovolemia" meddra_llt_id="10021139" meddra_pt="Hypovolaemia" meddra_pt_id="10021137" />
    </Mention>
    <Mention id="M201" len="5,10" reason="preexisting_condition_or_risk_factor" section="S3" start="13984,14001" type="Not_AE_Candidate">
      <Normalization meddra_llt="Renal impairment" meddra_llt_id="10062237" meddra_pt="Renal impairment" meddra_pt_id="10062237" />
    </Mention>
    <Mention id="M202" len="18" reason="preexisting_condition_or_risk_factor" section="S3" start="13993" type="Not_AE_Candidate">
      <Normalization meddra_llt="Hepatic impairment" meddra_llt_id="10052254" meddra_pt="Liver disorder" meddra_pt_id="10024670" />
      <Normalization meddra_pt="Hepatotoxicity" meddra_pt_id="10019851" />
    </Mention>
    <Mention id="M203" len="13" reason="preexisting_condition_or_risk_factor" section="S3" start="14013" type="Not_AE_Candidate">
      <Normalization meddra_llt="Heart failure" meddra_llt_id="10019279" meddra_pt="Cardiac failure" meddra_pt_id="10007554" />
    </Mention>
    <Mention id="M204" len="11" reason="preexisting_condition_or_risk_factor" section="S3" start="14028" type="Not_AE_Candidate">
      <Normalization meddra_llt="Dehydration" meddra_llt_id="10012174" meddra_pt="Dehydration" meddra_pt_id="10012174" />
    </Mention>
    <Mention id="M205" len="11" reason="preexisting_condition_or_risk_factor" section="S3" start="14044" type="Not_AE_Candidate">
      <Normalization meddra_llt="Hypovolemia" meddra_llt_id="10021139" meddra_pt="Hypovolaemia" meddra_pt_id="10021137" />
    </Mention>
    <Mention id="M185" len="13" reason="preexisting_condition_or_risk_factor" section="S3" start="14166" type="Not_AE_Candidate">
      <Normalization meddra_llt="Renal disease" meddra_llt_id="10051051" meddra_pt="Nephropathy" meddra_pt_id="10029151" />
    </Mention>
    <Mention id="M282" len="24" reason="AE_only_as_instruction" section="S3" start="14237" type="NonOSE_AE">
      <Normalization meddra_llt="Renal function abnormal" meddra_llt_id="10038451" meddra_pt="Renal impairment" meddra_pt_id="10062237" />
    </Mention>
    <Mention id="M186" len="13" reason="preexisting_condition_or_risk_factor" section="S3" start="14309" type="Not_AE_Candidate">
      <Normalization meddra_llt="Renal disease" meddra_llt_id="10051051" meddra_pt="Nephropathy" meddra_pt_id="10029151" />
    </Mention>
    <Mention id="M250" len="24" reason="AE_only_as_instruction" section="S3" start="14354" type="NonOSE_AE">
      <Normalization meddra_llt="Renal function abnormal" meddra_llt_id="10038451" meddra_pt="Renal impairment" meddra_pt_id="10062237" />
    </Mention>
    <Mention id="M330" len="42" reason="class_effect" section="S3" start="14402" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Potassium serum increased" meddra_llt_id="10036456" meddra_pt="Blood potassium increased" meddra_pt_id="10005725" />
    </Mention>
    <Mention id="M331" len="12" reason="class_effect" section="S3" start="14456" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hyperkalemia" meddra_llt_id="10020647" meddra_pt="Hyperkalaemia" meddra_pt_id="10020646" />
    </Mention>
    <Mention id="M206" len="16" reason="preexisting_condition_or_risk_factor" section="S3" start="14539" type="Not_AE_Candidate">
      <Normalization meddra_llt="Renal impairment" meddra_llt_id="10062237" meddra_pt="Renal impairment" meddra_pt_id="10062237" />
    </Mention>
    <Mention id="M211" len="37" reason="preexisting_condition_or_risk_factor" section="S3" start="14637" type="Not_AE_Candidate">
      <Normalization meddra_llt="Hyporeninemic hypoaldosteronism" meddra_llt_id="10053988" meddra_pt="Hypoaldosteronism" meddra_pt_id="10020944" />
    </Mention>
    <Mention id="M332" len="22" reason="from_drug_use" section="S3" start="14747" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Anaphylactic reaction" meddra_llt_id="10002198" meddra_pt="Anaphylactic reaction" meddra_pt_id="10002198" />
    </Mention>
    <Mention id="M212" len="30" reason="contraindication" section="S3" start="14805" type="Not_AE_Candidate">
      <Normalization meddra_llt="Drug hypersensitivity" meddra_llt_id="10013700" meddra_pt="Drug hypersensitivity" meddra_pt_id="10013700" />
      <Normalization meddra_pt="Hypersensitivity" meddra_pt_id="10020751" />
    </Mention>
    <Mention id="M187" len="24" reason="contraindication" section="S3" start="14857" type="Not_AE_Candidate">
      <Normalization meddra_llt="Aspirin-sensitive asthma" meddra_llt_id="10003534" meddra_pt="Aspirin-exacerbated respiratory disease" meddra_pt_id="10075084" />
    </Mention>
    <Mention id="M251" len="21" reason="AE_only_as_instruction" section="S3" start="14982" type="NonOSE_AE">
      <Normalization meddra_llt="Anaphylactic reaction" meddra_llt_id="10002198" meddra_pt="Anaphylactic reaction" meddra_pt_id="10002198" />
    </Mention>
    <Mention id="M355" len="53" reason="class_effect" section="S3" start="15021" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Analgesic asthma syndrome" meddra_llt_id="10063023" meddra_pt="Aspirin-exacerbated respiratory disease" meddra_pt_id="10075084" />
    </Mention>
    <Mention id="M188" len="6" reason="preexisting_condition_or_risk_factor" section="S3" start="15111" type="Not_AE_Candidate">
      <Normalization meddra_llt="Asthma" meddra_llt_id="10003553" meddra_pt="Asthma" meddra_pt_id="10003553" />
    </Mention>
    <Mention id="M189" len="24" reason="preexisting_condition_or_risk_factor" section="S3" start="15127" type="Not_AE_Candidate">
      <Normalization meddra_llt="Aspirin-sensitive asthma" meddra_llt_id="10003534" meddra_pt="Aspirin-exacerbated respiratory disease" meddra_pt_id="10075084" />
    </Mention>
    <Mention id="M207" len="14" reason="preexisting_condition_or_risk_factor" section="S3" start="15178" type="Not_AE_Candidate">
      <Normalization meddra_llt="Rhinosinusitis" meddra_llt_id="10052106" meddra_pt="Sinusitis" meddra_pt_id="10040753" />
    </Mention>
    <Mention id="M190" len="12" reason="preexisting_condition_or_risk_factor" section="S3" start="15208" type="Not_AE_Candidate">
      <Normalization meddra_llt="Nasal polyps" meddra_llt_id="10028756" meddra_pt="Nasal polyps" meddra_pt_id="10028756" />
    </Mention>
    <Mention id="M283" len="5" reason="general_term" section="S3" start="15242" type="NonOSE_AE">
      <Normalization meddra_llt="Death" meddra_llt_id="10011906" meddra_pt="Death" meddra_pt_id="10011906" />
    </Mention>
    <Mention id="M191" len="12" reason="preexisting_condition_or_risk_factor" section="S3" start="15248" type="Not_AE_Candidate">
      <Normalization meddra_llt="Bronchospasm" meddra_llt_id="10006482" meddra_pt="Bronchospasm" meddra_pt_id="10006482" />
    </Mention>
    <Mention id="M192" len="22" reason="preexisting_condition_or_risk_factor" section="S3" start="15269" type="Not_AE_Candidate">
      <Normalization meddra_llt="Drug intolerance" meddra_llt_id="10061822" meddra_pt="Drug intolerance" meddra_pt_id="10061822" />
    </Mention>
    <Mention id="M356" len="49" reason="class_effect" section="S3" start="15318" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Drug cross-reactivity" meddra_llt_id="10076743" meddra_pt="Therapeutic product cross-reactivity" meddra_pt_id="10079645" />
    </Mention>
    <Mention id="M208" len="6" reason="preexisting_condition_or_risk_factor" section="S3" start="15586" type="Not_AE_Candidate">
      <Normalization meddra_llt="Asthma" meddra_llt_id="10003553" meddra_pt="Asthma" meddra_pt_id="10003553" />
    </Mention>
    <Mention id="M252" len="6" reason="AE_only_as_instruction" section="S3" start="15688" type="NonOSE_AE">
      <Normalization meddra_llt="Asthma" meddra_llt_id="10003553" meddra_pt="Asthma" meddra_pt_id="10003553" />
    </Mention>
    <Mention id="M362" len="22" reason="from_drug_use" section="S3" start="15779" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Reaction skin" meddra_llt_id="10037971" meddra_pt="Skin reaction" meddra_pt_id="10040914" />
      <Normalization meddra_pt="Skin toxicity" meddra_pt_id="10059516" />
    </Mention>
    <Mention id="M333" len="22" reason="from_drug_use" section="S3" start="15810" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dermatitis exfoliative" meddra_llt_id="10012455" meddra_pt="Dermatitis exfoliative" meddra_pt_id="10012455" />
    </Mention>
    <Mention id="M334" len="24" reason="from_drug_use" section="S3" start="15834" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Syndrome Stevens-Johnson" meddra_llt_id="10042849" meddra_pt="Stevens-Johnson syndrome" meddra_pt_id="10042033" />
    </Mention>
    <Mention id="M335" len="26" reason="from_drug_use" section="S3" start="15870" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Toxic epidermal necrolysis" meddra_llt_id="10044223" meddra_pt="Toxic epidermal necrolysis" meddra_pt_id="10044223" />
    </Mention>
    <Mention id="M284" len="5" reason="general_term" section="S3" start="15917" type="NonOSE_AE">
      <Normalization meddra_llt="Death" meddra_llt_id="10011906" meddra_pt="Death" meddra_pt_id="10011906" />
    </Mention>
    <Mention id="M285" len="14" reason="AE_only_as_instruction" section="S3" start="16028" type="NonOSE_AE">
      <Normalization meddra_llt="Reaction skin" meddra_llt_id="10037971" meddra_pt="Skin reaction" meddra_pt_id="10040914" />
      <Normalization meddra_pt="Skin toxicity" meddra_pt_id="10059516" />
    </Mention>
    <Mention id="M253" len="9" reason="manifestation_or_complication" section="S3" start="16110" type="NonOSE_AE">
      <Normalization meddra_llt="Skin rash" meddra_llt_id="10040913" meddra_pt="Rash" meddra_pt_id="10037844" />
    </Mention>
    <Mention id="M254" len="16" reason="AE_only_as_instruction" section="S3" start="16141" type="NonOSE_AE">
      <Normalization meddra_llt="Hypersensitivity" meddra_llt_id="10020751" meddra_pt="Hypersensitivity" meddra_pt_id="10020751" />
      <Normalization meddra_pt="Drug hypersensitivity" meddra_pt_id="10013700" />
    </Mention>
    <Mention id="M209" len="24" reason="contraindication" section="S3" start="16221" type="Not_AE_Candidate">
      <Normalization meddra_llt="Reaction skin" meddra_llt_id="10037971" meddra_pt="Skin reaction" meddra_pt_id="10040914" />
      <Normalization meddra_pt="Skin toxicity" meddra_pt_id="10059516" />
    </Mention>
    <Mention id="M286" len="11" reason="AE_only_as_instruction" section="S3" start="16313" type="NonOSE_AE">
      <Normalization meddra_llt="Skin wound" meddra_llt_id="10072170" meddra_pt="Skin wound" meddra_pt_id="10072170" />
    </Mention>
    <Mention id="M287" len="10" reason="AE_only_as_instruction" section="S3" start="16326" type="NonOSE_AE">
      <Normalization meddra_llt="Infection" meddra_llt_id="10021789" meddra_pt="Infection" meddra_pt_id="10021789" />
    </Mention>
    <Mention id="M288" len="13" reason="AE_only_as_instruction" section="S3" start="16338" type="NonOSE_AE">
      <Normalization meddra_llt="Inflammation" meddra_llt_id="10061218" meddra_pt="Inflammation" meddra_pt_id="10061218" />
    </Mention>
    <Mention id="M289" len="22" reason="AE_only_as_instruction" section="S3" start="16356" type="NonOSE_AE">
      <Normalization meddra_llt="Dermatitis exfoliative" meddra_llt_id="10012455" meddra_pt="Dermatitis exfoliative" meddra_pt_id="10012455" />
    </Mention>
    <Mention id="M336" len="48" reason="from_drug_use" section="S3" start="16517" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Ductus arteriosus premature closure" meddra_llt_id="10049996" meddra_pt="Ductus arteriosus premature closure" meddra_pt_id="10049996" />
    </Mention>
    <Mention id="M210" len="8" reason="preexisting_condition_or_risk_factor" section="S3" start="16611" type="Not_AE_Candidate">
      <Normalization meddra_llt="Pregnant" meddra_llt_id="10036586" meddra_pt="Pregnancy" meddra_pt_id="10036556" />
    </Mention>
    <Mention id="M363" len="20" reason="from_drug_use" section="S3" start="16735" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hematotoxicity" meddra_llt_id="10061196" meddra_pt="Haematotoxicity" meddra_pt_id="10061188" />
      <Normalization meddra_pt="Blood disorder" meddra_pt_id="10061590" />
    </Mention>
    <Mention id="M337" len="6" reason="class_effect" section="S3" start="16759" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Anemia" meddra_llt_id="10002272" meddra_pt="Anaemia" meddra_pt_id="10002034" />
    </Mention>
    <Mention id="M213" len="10" reason="preexisting_condition_or_risk_factor" section="S3" start="16841" type="Not_AE_Candidate">
      <Normalization meddra_llt="Blood loss of (NOS)" meddra_llt_id="10005645" meddra_pt="Haemorrhage" meddra_pt_id="10055798" />
    </Mention>
    <Mention id="M214" len="15" reason="preexisting_condition_or_risk_factor" section="S3" start="16853" type="Not_AE_Candidate">
      <Normalization meddra_llt="Fluid retention" meddra_llt_id="10016807" meddra_pt="Fluid retention" meddra_pt_id="10016807" />
    </Mention>
    <Mention id="M215" len="24" reason="indication" section="S3" start="16899" type="Not_AE_Candidate">
      <Normalization meddra_llt="Erythropoiesis abnormal" meddra_llt_id="10049467" meddra_pt="Erythropoiesis abnormal" meddra_pt_id="10049467" />
    </Mention>
    <Mention id="M255" len="6" reason="AE_only_as_instruction" section="S3" start="16989" type="NonOSE_AE">
      <Normalization meddra_llt="Anemia" meddra_llt_id="10002272" meddra_pt="Anaemia" meddra_pt_id="10002034" />
    </Mention>
    <Mention id="M338" len="8" reason="from_drug_use" section="S3" start="17086" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Bleeding" meddra_llt_id="10005103" meddra_pt="Haemorrhage" meddra_pt_id="10055798" />
    </Mention>
    <Mention id="M193" len="21" reason="preexisting_condition_or_risk_factor" section="S3" start="17132" type="Not_AE_Candidate">
      <Normalization meddra_llt="Disorder coagulation" meddra_llt_id="10013206" meddra_pt="Coagulopathy" meddra_pt_id="10009802" />
    </Mention>
    <Mention id="M256" len="8" reason="AE_only_as_instruction" section="S3" start="17400" type="NonOSE_AE">
      <Normalization meddra_llt="Bleeding" meddra_llt_id="10005103" meddra_pt="Haemorrhage" meddra_pt_id="10055798" />
    </Mention>
    <Mention id="M366" len="23" reason="from_drug_use" section="S3" start="17454" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Inflammation masked" meddra_llt_id="10079680" meddra_pt="Inflammation masked" meddra_pt_id="10079680" />
    </Mention>
    <Mention id="M367" len="10,5" reason="from_drug_use" section="S3" start="17454,17482" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Masked fever" meddra_llt_id="10079681" meddra_pt="Masked fever" meddra_pt_id="10079681" />
    </Mention>
    <Mention id="M298" len="21" reason="AE_only_as_instruction" section="S3" start="17535" type="NonOSE_AE">
      <Normalization meddra_llt="Drug therapy" meddra_llt_id="10063370" meddra_pt="Drug therapy" meddra_pt_id="10063370" />
      <Normalization meddra_pt="Immunoglobulin therapy" meddra_pt_id="10069534" />
    </Mention>
    <Mention id="M299" len="8,5" reason="AE_only_as_instruction" section="S3" start="17535,17571" type="NonOSE_AE">
      <Normalization meddra_llt="Drug therapy" meddra_llt_id="10063370" meddra_pt="Drug therapy" meddra_pt_id="10063370" />
      <Normalization meddra_pt="Immunoglobulin therapy" meddra_pt_id="10069534" />
    </Mention>
    <Mention id="M290" len="10" reason="AE_only_as_instruction" section="S3" start="17636" type="NonOSE_AE">
      <Normalization meddra_llt="Infection" meddra_llt_id="10021789" meddra_pt="Infection" meddra_pt_id="10021789" />
    </Mention>
    <Mention id="M301" len="11" reason="AE_only_as_instruction" section="S3" start="17699" type="NonOSE_AE">
      <Normalization meddra_llt="GI bleed" meddra_llt_id="10018230" meddra_pt="Gastrointestinal haemorrhage" meddra_pt_id="10017955" />
    </Mention>
    <Mention id="M302" len="14" reason="AE_only_as_instruction" section="S3" start="17712" type="NonOSE_AE">
      <Normalization meddra_llt="Hepatotoxicity" meddra_llt_id="10019851" meddra_pt="Hepatotoxicity" meddra_pt_id="10019851" />
      <Normalization meddra_pt="Liver disorder" meddra_pt_id="10024670" />
    </Mention>
    <Mention id="M303" len="12" reason="AE_only_as_instruction" section="S3" start="17732" type="NonOSE_AE">
      <Normalization meddra_llt="Renal injury" meddra_llt_id="10061481" meddra_pt="Renal injury" meddra_pt_id="10061481" />
    </Mention>
    <Mention id="M291" len="37" reason="AE_animal" section="S3" start="18169" type="NonOSE_AE">
      <Normalization meddra_llt="Skin tumor" meddra_llt_id="10040940" meddra_pt="Neoplasm skin" meddra_pt_id="10029098" />
    </Mention>
    <Mention id="M292" len="35" reason="AE_only_as_instruction" section="S3" start="18245" type="NonOSE_AE">
      <Normalization meddra_llt="Application site photosensitivity reaction" meddra_llt_id="10058730" meddra_pt="Application site photosensitivity reaction" meddra_pt_id="10058730" />
    </Mention>
    <Mention id="M257" len="3,10" reason="AE_only_as_instruction" section="S3" start="18449,18501" type="NonOSE_AE">
      <Normalization meddra_llt="Irritation eye" meddra_llt_id="10023013" meddra_pt="Eye irritation" meddra_pt_id="10015946" />
    </Mention>
    <Mention id="M258" len="17" reason="AE_from_drug_interaction" section="S3" start="18678" type="NonOSE_AE">
      <Normalization meddra_llt="Hemorrhage rectal" meddra_llt_id="10019583" meddra_pt="Rectal haemorrhage" meddra_pt_id="10038063" />
    </Mention>
    <Mention id="M259" len="19" reason="AE_from_drug_interaction" section="S3" start="18711" type="NonOSE_AE">
      <Normalization meddra_llt="Plasma creatinine abnormal" meddra_llt_id="10035276" meddra_pt="Blood creatinine abnormal" meddra_pt_id="10005481" />
    </Mention>
    <Mention id="M260" len="8,4" reason="AE_from_drug_interaction" section="S3" start="18711,18732" type="NonOSE_AE">
      <Normalization meddra_llt="Plasma urea abnormal" meddra_llt_id="10035459" meddra_pt="Blood urea abnormal" meddra_pt_id="10005846" />
    </Mention>
    <Mention id="M261" len="8,10" reason="AE_from_drug_interaction" section="S3" start="18711,18741" type="NonOSE_AE">
      <Normalization meddra_llt="Hemoglobin abnormal" meddra_llt_id="10019482" meddra_pt="Haemoglobin abnormal" meddra_pt_id="10018879" />
    </Mention>
  </Mentions>
</GoldLabel>